COMPLIANCE TO GUIDELINES AND ROLE OF PATIENTS IN MANAGEMENT OF TYPE 2 DIABETES AMONG PATIENTS IN VIHIGA COUNTY REFERRAL HOSPITAL, KENYA

Kaitany Benjamin Kiplagat, B. Pharm
Reg: U51/75336/2014

A Research thesis submitted in partial fulfilment of the requirements for the award of Master of Pharmacy in Pharmacoepidemiology and Pharmacovigilance

Department of Pharmacology and Pharmacognosy
School of Pharmacy
University of Nairobi

November 2016
UNIVERSITY OF NAIROBI STATEMENT OF ORIGINALITY

Name of Student: Kaitany Benjamin Kiplagat
Registration Number: U51/75336/2014
College: College of Health Sciences
School: Pharmacy
Department: Pharmacology and Pharmacognosy
Course Name: Master of Pharmacy in Pharmacoepidemiology and Pharmacovigilance
Title of the work: Management of Type 2 diabetic patients according to protocols and assessment of opinions and practices on responsibility at Vihiga County Referral Hospital.

1. I understand what Plagiarism is and I am aware of the University’s policy in this regard
2. I declare that this research Thesis is my original work and has not been submitted elsewhere for examination, award of a degree or publication. Where other people’s work or my own work has been used, this has properly been acknowledged and referenced in accordance with the University of Nairobi’s requirements.
3. I have not sought or used the services of any professional agencies to produce this work
4. I have not allowed, and shall not allow anyone to copy my work with the intention of passing it off as his/her own work
5. I understand that any false claim in respect of this work shall result in disciplinary action, in accordance with University Plagiarism Policy.

Signature ___________________ Date________________________________
DECLARATION

I, Kaitany Benjamin Kiplagat do hereby declare that this thesis is my original work and that this work has not been presented for the award of any other degree or to any other university.

Signed………………………………………………………………..
Date………………………………………………………………..

Kaitany Benjamin Kiplagat, Bpharm

SUPERVISORS’ APPROVAL

This thesis has been submitted with our approval as University supervisors:

1. Dr. Eric M. Guantai
   Department of Pharmacology and Pharmacognosy
   Sign---------------------Date----------------------

2. Dr. Beatrice K. Amugune
   Department of Pharmaceutical Chemistry
   Sign---------------------Date----------------------

3. Dr. Mercy N. Mulaku
   Department of Pharmacology and Pharmacognosy
   Sign---------------------Date----------------------
ACKNOWLEDGEMENTS

I would like to thank the Almighty God for the day to day guidance, strength and protection.

For the creation of this thesis, I want to sincerely thank my supervisors for their invaluable assistance, motivation and technical support; Dr. Eric M. Guantai, Dr. Beatrice M. Amugune and Dr. Mercy N. Mulaku, who worked with me to ensure completion of this work.

I convey my deepest gratitude to my beloved parents, Mr. and Mrs. Ernest Kaitany, for always praying for me and for constantly encouraging me to work hard all my life, most specifically as I pursued my studies.

My thanks to my siblings Joan, Joram, Oscar and Fridah and their respective families for lighting up my life every single day and for their never ending love and support through the good times as well as the challenging moments of life.

Special thanks to my best friend Daniel Kasika for the non-reluctant support, encouragement and assistance he offered me whenever I called upon him. Thanks to Anne Mueni who supported me all through with my work. Thanks to Caroline Muhati who encouraged me to pursue higher learning and walked me through it.
TABLE OF CONTENTS
DECLARATION .................................................................................................................... iii
ACKNOWLEDGEMENTS .................................................................................................... iv
LIST OF TABLES ................................................................................................................ viii
LIST OF FIGURES ............................................................................................................ ix
LIST OF ACRONYMS AND ABBREVIATIONS ................................................................. x
ABSTRACT ......................................................................................................................... xi
CHAPTER ONE ................................................................................................................... 1
1. INTRODUCTION ............................................................................................................. 1
   1.1 BACKGROUND ........................................................................................................... 1
   1.2 PROBLEM STATEMENT ............................................................................................ 2
   1.3 RESEARCH QUESTIONS .......................................................................................... 3
   1.4 OBJECTIVES OF THE STUDY ................................................................................ 3
       1.4.1 Main objective ................................................................................................... 3
       1.4.2 Specific objectives ........................................................................................... 4
   1.5 JUSTIFICATION OF THE STUDY ......................................................................... 4
CHAPTER TWO .................................................................................................................. 5
2. LITERATURE REVIEW ................................................................................................... 5
   2.1 Treatment Guidelines in management of Diabetes .................................................... 5
   2.2 Roles of clinicians, pharmacists, nurses and nutritionists in patient care ................... 6
   2.3 PATIENTS RESPONSIBILITY IN MANAGING DIABETES ....................................... 6
       2.3.1 Nutrition management by patients ................................................................... 6
       2.3.2 Patient involvement in physical activity ............................................................ 7
       2.3.3 Home based Self-monitoring of blood glucose ................................................ 8
       2.3.4 Compliance with anti-diabetic medication ......................................................... 8
   2.4 DIABETES ASSOCIATED COMPLICATIONS ......................................................... 9
   2.5 TREATMENT TARGET RECOMMENDATIONS FOR DIAGNOSIS AND MONITORING 9
   2.6 CONCEPTUAL FRAMEWORK ................................................................................. 12
CHAPTER THREE ............................................................................................................. 13
3. METHODS ...................................................................................................................... 13
   3.1 STUDY SITE ............................................................................................................. 13
   3.2 RETROSPECTIVE CROSS SECTIONAL AUDIT ..................................................... 14
3.2.1 Study design and Population

3.2.2 Inclusion and exclusion criteria for the clinical audit

3.2.3 Sample size for the clinical audit

3.2.4 Sampling method

3.2.5 Data collection

3.3 PROPECTIVE PATIENT SURVEY

3.3.1 Study design and Population

3.3.2 Sample size

3.3.3 Sampling method

3.3.4 Participant recruitment and Data collection

3.4 DATA MANAGEMENT

3.5 QUALITY ASSURANCE

3.5.1 STUDY VARIABLES

3.6 DATA ANALYSIS

3.7 ETHICAL CONSIDERATIONS

CHAPTER FOUR

4. RESULTS

4.1 RETROSPECTIVE CROSS SECTIONAL AUDIT OF COMPLIANCE TO TREATMENT GUIDELINES

4.1.1 Patient demographics and clinical characteristics

4.1.2 Prescriber information

4.1.3 Compliance to guidelines on diagnosis, drug selection and monitoring of diabetes

4.1.4 Method of diagnosis and medication selection at treatment initiation

4.1.5 Blood pressure, cholesterol and weight monitoring at initiation

4.1.6 Monitoring and Attainment of treatment therapeutic targets for Sugar, Blood pressure, lipid levels, weight and renal function on follow up

4.3 PREVALENCE AND RISK FACTORS FOR COMPLICATIONS ASSOCIATED WITH TYPE 2 DIABETES

4.3.1 Risk factors of Retinopathy

4.3.2 Risk factors for neuropathy

4.4 PROSPECTIVE SURVEY OF PARTICIPANTS ON SELF-CARE BEHAVIOURS IN TYPE TWO DIABETES
4.4.1 Patient demographic characteristics .......................................................... 29
4.4.2 Participant perceived adequacy of glycemic control ........................................ 29
4.4.3 Knowledge and practice of dietary control of diabetes ....................................... 30
4.4.4 Barriers to dietary practices ........................................................................... 31
4.4.5 Participant reported adherence to medication .................................................... 32
4.4.6 Participant barriers to medication use ................................................................ 32
4.4.7 Participant blood glucose monitoring practices .................................................. 33
4.4.8 Engaging in routine physical activity ............................................................... 34
4.4.9 Factors hindering participants from engaging in exercises .................................. 34
4.4.10 Overall assessment on patient self care behaviour ......................................... 34

CHAPTER FIVE ........................................................................................................... 35

5. DISCUSSION ........................................................................................................ 35

CHAPTER SIX .......................................................................................................... 39

6. CONCLUSION AND RECOMMENDATIONS ...................................................... 39

6.1 Conclusion ......................................................................................................... 39
6.2 Recommendations ............................................................................................ 39

6.2.1 Recommendation for practice ....................................................................... 39
6.2.2 Recommendation for future research ............................................................. 40

REFERENCES .......................................................................................................... 41

APPENDIX 1: DATA COLLECTION FORM FOR PATIENT’S DEMOGRAPHICS AND
INFOFROMATION ON COMPLIANCE TO ICSI TREATMENT GUIDELINES .................... 44

STUDY TITLE: COMPLIANCE WITH GUIDELINES AND THE ROLE OF PATIENTS IN
MANAGEMENT OF TYPE 2 DIABETIC PATIENTS AT VIHIGA COUNTY REFERRAL
HOSPITAL, KENYA. .................................................................................................. 44

APPENDIX 2: INFORMED CONSENT PROCESS INFORMATION AND CONSENT FORM ....... 46

APPENDIX 3: DATA COLLECTION FORM (QUESTIONNAIRE) FOR PATIENTS’
DEMOGRAPHICS AND INFOMATION ON OPINIONS WITH REGARD TO PRACTICES ON
SELF CARE BEHAVIOURS ...................................................................................... 49

APPENDIX 4: KNH-UON ERC APPROVAL LETTER ..................................................... 70
LIST OF TABLES

Table 1: Ranges of self-monitored blood glucose values for various A1c goals………………10

Table 2: HbA1c and corresponding blood glucose levels……………………………………11

Table 3: Distribution of patients according to Age, gender and duration of illness……………20

Table 4: Compliance to guidelines for diagnosis, management and monitoring of diabetic therapy……………………………………………………………………………………………………………………22

Table 5: Attainment of treatment targets on follow up between January and June, 2015……..24

Table 6: Summary of the risk factors for retinopathy………………………………………..26

Table 7: Summary of the risk factors for neuropathy…………………………………………28
LIST OF FIGURES

Figure 1 Conceptual framework for determinants of quality of care in diabetic patients……12
Figure 2 Healthcare providers at initiation of therapy........................................21
Figure 3 Prevalence of micro-vascular and other complications of Type 2 diabetes.........26
Figure 4 Patient Demographic details.................................................................30
Figure 5 Participant dietary knowledge and practices.............................................31
Figure 6 Barriers to dietary adherence and instructions..........................................32
Figure 7 Factors hindering effective medication use.............................................33
LIST OF ACRONYMS AND ABBREVIATIONS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>DSME</td>
<td>Diabetes self-management education</td>
</tr>
<tr>
<td>ESMON</td>
<td>Efficacy of Self-Monitoring of Blood Glucose</td>
</tr>
<tr>
<td>FBG</td>
<td>Fasting Blood Glucose</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development and Evaluation</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Glycated Haemoglobin</td>
</tr>
<tr>
<td>HDL-C</td>
<td>High Density Lipoprotein Cholesterol</td>
</tr>
<tr>
<td>IDF</td>
<td>International Diabetic Federation</td>
</tr>
<tr>
<td>ICSI</td>
<td>Institute for Clinical Systems Improvement</td>
</tr>
<tr>
<td>KNH</td>
<td>Kenyatta National Hospital</td>
</tr>
<tr>
<td>LDL-C</td>
<td>Low Density Lipoprotein Cholesterol</td>
</tr>
<tr>
<td>MOPC</td>
<td>Medical Outpatient Clinic</td>
</tr>
<tr>
<td>OGTT</td>
<td>Oral Glucose Tolerance Test</td>
</tr>
<tr>
<td>RBS</td>
<td>Random Blood Sugar</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic Blood Pressure</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td>UON</td>
<td>University Of Nairobi</td>
</tr>
<tr>
<td>VCRH</td>
<td>Vihiga County Referral Hospital</td>
</tr>
</tbody>
</table>
ABSTRACT

Introduction: The incidence of diabetes is increasing in Kenya, and poor diabetic related outcomes such as complications, high blood sugar levels have resulted due to inadequate management of the condition. However, the majority of the rural population in Kenya are highly ignorant of the common aetiologies and risk factors for diabetes. Patient awareness and involvement in self-care is very critical in improving outcomes and this should be part of treatment plan offered to them. The health care team should adopt standard treatment guidelines that are practical, evidence based, valid and up-to date in management of diabetic patients.

Objective: To assess compliance to guidelines, prevalence of diabetic complications and role of patients in management of Type 2 diabetes at a rural set up in Kenya.

Methods: Two cross-sectional studies consisting of a retrospective audit of prescribing and monitoring practices and a prospective patient survey on self-practice were conducted. The target population was Type 2 diabetic patients attending medical outpatient clinic at Vihiga County Referral Hospital. Inferential statistics using t-test and Mann-Whitney test was done and bivariable logistic regression analysis carried out. Model building was done to come up with a parsimonious model using IBM SPSS® Statistics version 22 database.

Results and Discussion: A total of 212 patient files were retrieved. The participants aged 50 – 69 years were 60% and females were the most in the study at 70.3%. Most (39.6%) had had diabetes for 1 to 5 years. Random blood Sugar test was the most used method of diagnosis (58.5%) whilst FBG was performed in 34% of the participants tested. Metformin was part of first line therapy with a compliance rate of 72.2%. Compliance to ICSI recommendations with regard to blood pressure, weight and cholesterol monitoring at initiation was 96.7, 1.4 and 6.1% respectively. Of the 141 patients that had their fasting blood sugar monitored, 113 (80.1%) had uncontrolled blood sugar levels. The median blood glucose for all patients tested with FBG was significantly higher than the target threshold of 7 mmol/L (median blood sugar = 8.9(IQR.7.4, 12.75) mmol/L; P=0.741). The prevalence of the major diabetic complications: neuropathy, retinopathy and nephropathy were 41, 33 and 0.9% respectively. There was an association between fasting blood glucose level and retinopathy and neuropathy. Total of 25 participants were recruited into the survey and most of them did not experiencing challenges in executing
self-care behaviours to managing their condition. Use of treatment guidelines will help improve the quality of clinical decision made by healthcare workers, improve health outcomes. Diabetic patient education should also be encouraged to enhance and improve patient self-care behaviours.

**Conclusion:** Patients were not adequately being diagnosed, managed and monitored as per the ICSI treatment guideline recommendations. There was high prevalence of retinopathy and neuropathy. Uncontrolled hypertension and fasting glucose levels were significant risk factors for complications. Patients lack on knowledge on nutritional interventions. Hence there is need to strengthen capacity to manage type 2 diabetes in this facility.
CHAPTER ONE

1. INTRODUCTION

1.1 BACKGROUND

In 2013, global estimates showed that almost 382 million people suffered from diabetes indicating a prevalence of 8.3%. The African diabetic prevalence in the same year was 4.9% representing an approximate population of 19.8 million adults. The prevalence of diabetes in The Island of Réunion, Seychelles, Gabon and Zimbabwe are 15.4, 12.1, 10.7 and 9.7% respectively. The most populous African countries with the highest numbers of diabetics include Nigeria, South Africa, Ethiopia and the United Republic of Tanzania with a diabetic population of 3.9, 2.6, 1.9, 1.7 million respectively [1]. In Kenya, diabetic epidemiology has not been studied to a far extent. Although the prevalence as at 2013 is from an opportunity sample of an urban and rural population that reported value of 4.2% [2].

Diabetes is a long term condition that develops when the body insufficiently produces enough insulin or cannot effectively use it. Insulin is a hormone produced in the pancreas that allows glucose from food to enter the body’s cells. It is converted into energy required by muscles and tissues to function. Diabetics do not absorb glucose properly resulting to excess glucose circulating in the blood. This leads to damaging of body tissues over time culminating to disabling and life-threatening health complications [1].

Type 2 diabetes has frequently been seen in adults, although more incidences have risen in children and adolescents. Diabetics either cannot produce enough insulin or develop insulin resistance which results from excess build-up of glucose in the blood [1].

Diabetics must receive care from an integrated team of diabetes experts constituting of pharmacists, physicians, nurses and nutritionists. Diabetics must also participate actively in their care. A diabetes management plan should be formulated by incorporating all the ideas from the patient and family and the healthcare team. The plan should also include continuous program of patient support and diabetes education on self management. Treatment goals and plans should as much as possible be specific to individual patient. Amongst factors to be considered when developing the plan are the age of patient, daily routine timetable, social and cultural factors, diabetic complications, and other co-morbidities [3].
Lifestyle change remains an integral part of treatment of type 2 diabetes. The most important choices affecting the health of an individual are instituted by that person and not by the health professionals [4]. Diabetic outcomes can thus be improved by increased involvement of diabetic patient in making decisions surrounding their care. Healthcare providers may face challenges such as limited time while engaging in a participatory way with people with Type 2 diabetes [5].

Acknowledging the important roles played by health practitioners and the patients, this study therefore set out to assess the outpatient management of Type 2 diabetes as well as explore the opinions of the patients on practices regarding taking responsibility for their condition.

1.2 PROBLEM STATEMENT

The occurrence of diabetes is on the rise in Kenya [2], and poor diabetic related outcomes such as complications, high blood sugar levels and being overweight have resulted due to inadequate management of the condition. However, the majority of the rural population in Kenya are highly ignorant of the common aetiologies and risk factors for diabetes[15].

In Vihiga County Referral Hospital, diabetes mellitus is estimated to be the 6th most common cause of mortality and 7th highest cause of morbidity (injury or disease) in hierarchy of conditions most commonly managed. From July to December 2014, 974 patient visits were recorded at the clinic while 1,483 were for January to June 2015. Diabetic patients in Vihiga County Hospital attend a medical outpatient clinic held once a week and a review scheduled every after 2-3 months. For most part, the patients are expected to take responsibility for the management of their condition in between the periodic visits. Type 2 Diabetes remains a chronic illness that extensively affects the quality of life of patients if not properly managed, whereby both the healthcare practitioners and patients have important roles to play.

Diabetes treatment guidelines are intended to provide clinicians, patients, researchers and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. It is, therefore necessary to uphold compliance to these guidelines. Patient awareness and involvement in self-care is very critical in improving outcomes and this should be part of treatment plan offered to them.
Compliance to T2DM treatment guidelines by clinicians as well as patient awareness and involvement in self-care are inadequately studied in our setting. This study intended to address this knowledge gap by establishing the extent to which guidelines are adhered to and exploring patient adoption of self-care activities at a county referral hospital in Kenya. The lack of adherence to guidelines leads to a high prevalence of complications. The prevalence of diabetic complications in rural outpatient setting like Vihiga County is unknown. Hence this study sought to measure the prevalence of diabetic complications and patient engagement in disease management.

1.3 RESEARCH QUESTIONS

i. What is the proportion of adult Type 2 diabetic cases that are diagnosed, managed and monitored in accordance with ICSI treatment guidelines?

ii. What proportion of type 2 diabetic patients achieve the standard treatment targets for adequate disease control for HbA1c/FBG/OGTT, blood pressure, cholesterol and weight/BMI as outlined in the ICSI treatment guidelines?

iii. What is the prevalence and risk factors for diabetic complications?

iv. What are the patients’ opinions and practices with regards to taking responsibility for management of diabetes through consuming healthy food, engaging in physical activity, self-tracking of blood glucose levels and compliance with medication?

1.4 OBJECTIVES OF THE STUDY

1.4.1 Main objective

The main objective was to determine if outpatient management of Type 2 diabetes mellitus complies with the treatment guidelines and explore patients’ opinions on their roles to self care behaviours at Vihiga County Referral Hospital.
1.4.2 **Specific objectives**

The specific objectives were to:

i. Determine the proportion of adult Type 2 diabetes cases diagnosed, managed and monitored in accordance with ICSI treatment guidelines.

ii. Establish the proportion of type 2 diabetic patients who achieve the standard treatment targets for adequate disease control.

iii. Determine the prevalence and risk factors for diabetic complications

iv. Explore patients’ opinions and practices with regard to taking responsibility for management of diabetes through consuming healthy food, engaging in physical activity, self-tracking of blood glucose levels and compliance with medication.

1.5 **JUSTIFICATION OF THE STUDY**

This study set to identify the gaps in the adherence of clinical treatment guidelines by clinicians in management of type 2 diabetes. The findings from the study will enable the policy makers identify the areas where improvement should be emphasised on terms of utilization of treatment guidelines. If these gaps are addressed, hopefully this would lead to reduced incidence of diabetic related complications. The study also sought to provide baseline data on the prevalence of diabetic complications in an understudied rural setting. This data can be used as a reference point against which the effectiveness of any future intervention to improve diabetic management can be measured. Lastly, gaps in patient driven interventions were identified and these will form the basis of impetus to improve non pharmacological interventions.
CHAPTER TWO

2. LITERATURE REVIEW

2.1 Treatment Guidelines in management of Diabetes

In management of Diabetes Mellitus, it is important that health practitioners use an evidence-based, clear, valid and up to date document as a reference guide. It has been shown in rigorous evaluations that the greatest benefit of using clinical practice guidelines is to improve the quality of care received by patients. However, this may not be adequately achieved in daily practice probably because stakeholders in healthcare sector have varying definitions of quality and little is known on the effectiveness of guidelines [6].


The Guidelines were developed on basis of the Clinical guidelines for Management of Diabetes in Sub Sahara started by the International Diabetes Federation Africa. It was anticipated that regular reviews of the guidelines would be important to add in any new development as it becomes available from time to time[7]. Up to the time of this research, there has not been any update and review of the document.

The Institute for Clinical Systems Improvement (ICSI) Healthcare guideline for Diagnosis and Management of Type 2 Diabetes Mellitus[8] was used in this study. This guideline was developed by ICSI member working groups on basis of a systematic evidence review assessing literature produced on type 2 diabetes mellitus (T2DM). The databases looked into included PubMed and Cochrane with only studies done in the English language considered in the search. Amongst the searches carried out and used to come up with the document were on screening, diagnosis, diagnostic testing, risk factors, blood pressure, and lipid management. Review of several evidence rating and recommendation writing systems, led to ICSI’s decision to adopt to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology [8]. The Kenya National Clinical Guidelines for
Management of Diabetes Mellitus was used in areas where the ICSI guideline was not applicable.

2.2 Roles of clinicians, pharmacists, nurses and nutritionists in patient care

Health care professionals should educate patients on the essence of good diabetic management including provision of knowledge on lifestyle changes. However, various societal factors influence the ability of diabetics to manage their conditions and this poses a great challenge.

A coordinated interaction between patients and healthcare providers to achieve equitable, safe, effective and high-quality care for patients across the spectrum of type 2 diabetes is therefore required. In addition, there must be a healthcare system that focuses on improving the patient experience and outcomes throughout the continuum of care. There is need for adequate systems and support, resources and proper communication strategies for healthcare providers to effect change in patients’ lifestyles [9]

2.3 Patients responsibility in managing diabetes

Self-care in diabetes is a process by which diabetics develop awareness through learning to pull through with the complicated nature of the condition in a social setting. Diabetes daily care activities are overseen by patients themselves and/or family, therefore authentic measures for self-management should be provided to them [10].

2.3.1 Nutrition management by patients

The most demanding section of the treatment schedule for several diabetics is to know what to eat. Nutrition remedy is a fundamental element of diabetes prevention, control, and education on self-management. A trained nutritionist who has the knowledge and skills to provide diabetes management should provide each patient with individualized medical nutrition therapy [3].

The goals of nutrition therapy in adult diabetic patients are to eat healthy and, taking variety of foods in appropriate portions. Second is to deal with each ones’ nutritional requirements with focus on individual and cultural priorities, health competence and access to healthy food option, readiness and capacity to make behavioural changes. Finally is to maintain
pleasurable eating and provide the individual with practical tools for daily meal planning rather than focusing on individual macronutrients, micro-nutrients, or single foods.

2.3.2 Patient involvement in physical activity

Exercise is an integral issue in a management schedule for diabetes. Routine exercise has proven to enhance blood sugar management, bring down cardiovascular uncertainties, contribute to weight loss, and upgrade well-being[10]. The World Health Organisation 2010 recommended that adults over 18 years perform at least 150 minutes per week of moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity. If possible, both activities can be done. In addition, adults should perform activities that strengthen muscles twice or more a week. Adults 65 years of age and over are advised to abide by these recommendations or be physically active as much as possible. Studies in a meta-analysis of effects of exercise interventions on glycaemic control had a mean of 3.4 sessions per week, with a mean of 49 minutes per session[11]. The study showed that exercise training brings down glycated haemoglobin (HbA(1c)) by an amount that should reduce the danger of diabetic complications; but no significantly difference in body mass was found when exercise groups were compared with control groups.

The uptake of exercise in presence of long term specific diabetic complications has also been investigated. Caution is however necessary when a patient has retinopathy, peripheral neuropathy, autonomic neuropathy, albuminuria and nephropathy. Vigorous aerobic or resistance exercise may be contraindicated when proliferative diabetic retinopathy or severe non proliferative diabetic retinopathy is present. This is because there is high risk of triggering vitreous haemorrhage or retinal detachment[12].

For peripheral neuropathy, some exercises lead to reduced pain sensation and higher pain threshold in the extremities, which may result to increased risk of skin infection and Charcot joint destruction. However, some studies show that walking with average-intensity may not result to more danger of developing foot ulcers. In addition, patients with milder forms of neuropathy reported improved outcomes when they got involved in moderate exercise lasting 150 minutes per week [13]. Wearing proper footwear and daily feet examination to detect lesions should be done by all people with peripheral neuropathy. Similarly, those with a foot injury or open sore must be restricted to non–weight-bearing activities[14].
Reduced cardiac receptiveness to exercise, impaired night vision, altered body temperature regulation, postural hypotension, and altered papillary reaction can result to increased risk of exercise-induced injury in people with autonomic neuropathy [13]. Autonomic neuropathy in the cardiovascular system is a sole risk factor for silent myocardial ischemia and cardiovascular death[11]. Therefore, those with this type of neuropathy should be taken through cardiac examination before the start of physical activity which may be more vigorous than that they are used to.

It has been reported that labor intensive activities can sharply increase urinary protein elimination. On contrary, no proof has shown that hard exercise increases the rate of advancement of diabetic kidney disease, and therefore no need to prescribe specific restrictive exercises to diabetics with kidney disease[14].

2.3.3 Home based Self-monitoring of blood glucose

Self-monitoring of blood glucose is the cornerstone of diabetic care that can ensure patient participation in achieving and maintaining specific glycaemic targets. Self-monitoring provides information about current glycaemic status and allows assessment of therapy and guiding adjustments in diet, exercise and medication in order to achieve optimal glycaemic controls[10]. Self-monitoring should only be considered when the person with diabetes is prepared to learn the skills, record the findings, understand the data and act appropriately on the data [3]. However, personal monitoring of blood sugars in those diagnosed for the first time with type 2 diabetes was found to have no advantage in improving glycaemic control compared to non-monitoring[15].

2.3.4 Compliance with anti-diabetic medication

Noncompliance to prescribed anti-diabetic medication is a significant problem and a common occurrence which leads to unnecessary distress and reduced drug efficacy. It was reported in Cramer’s review on adherence in the treatment of diabetes, hypertension and dyslipidaemia that 30% of days 'on therapy' are not covered by medication. Only 59% of patients were taking medication for more than 80% of their days 'on therapy' in a year. Diabetes management may be enhanced by enhancing patient compliance because it is evident that good medication compliance has a useful effect on clinical outcomes[16]. Two studies showed 53 and 67% oral medications adherence levels in type 2 diabetics when determined
by electronic tracking. In a more recent study of elderly type 2 diabetic patients’ sulfonylureas compliance levels, determined by pill counts was at 104% to a once daily regimen and 87% to a two- or three times daily regimens. In this however, electronic tracking revealed lower adherence rates of 94 and 57% for once a daily and two or three times daily regimens, respectively[17].

### 2.4 DIABETES ASSOCIATED COMPLICATIONS

Diabetics can survive for many years without exhibiting any signs. Contrary, during then hyperglycemia is slowly destroying the body and diabetic related complications may be developing. The direct and indirect effects on the human vascular tree are the major source of morbidity and mortality in diabetes. Generally, the harmful effects of hyperglycemia are divided into macrovascular complications (coronary artery disease, peripheral arterial disease, and stroke) and microvascular complications (diabetic nephropathy, neuropathy, and retinopathy)[18].

In a study by Litwak et al, diabetes complication rates were high with 27.2% for macrovascular complications and 53.5% for microvascular complications and use of vascular disease preventative drugs lower than expected. Predictor variables to complications including age, body mass index (BMI), diabetes duration, low density lipoprotein cholesterol (LDL-C), and systolic bloodpressure (SBP) were positively associated, while high density lipoprotein cholesterol (HDL-C) was negatively associated, with macro- and microvascular complications. Glycated haemoglobin and fasting plasma glucose (FPG) were negatively associated with macrovascular complications[19].

Approximately 10,000 incidences of blindness occur yearly in the United States alone are as a result of retinopathy and may develop 7 years before diagnosis of diabetes. Nephropathy accounts for 7% of type 2 diabetes patients as at the time of diagnosis. Development of diabetic neuropathy is proportional to both the magnitude and duration of hyperglycemia[18].

### 2.5 TREATMENT TARGET RECOMMENDATIONS FOR DIAGNOSIS AND MONITORING

In management of type 2 diabetes, it is important to select specific improvement measures and goals which involve focusing on glucose, lipid and blood pressure regulation. This
strategy has proven to be successful in stopping up to 53% of heart attacks and strokes which are the main causes of death and excess costs in diabetics.

Type 2 diabetes should be diagnosed using glycated haemoglobin test, fasting glucose levels or Oral glucose tolerance test. Glycated Hemoglobin levels greater than 6.5% and fasting plasma glucose levels greater than 126 mg/dL, are indicative of diabetes. Similarly two hour plasma glucose greater than 200 mg/dl on a 75 g Oral Glucose Tolerance Test are indicative of diabetes [8]. Additionally, a person with symptoms of hyperglycemia and casual plasma glucose or random blood sugar (RBS) greater than 200 mg/dL (≥ 11.1 mmol/L), diabetes may be diagnostic [7].

Diabetic patients’ glucose levels should be monitored to achieve glycemic control with glycated haemoglobin of less than 53 mmol/mol or less than 7%. Due to normal variation in test accuracy, HbA1c results ranging between 6.5 and 7.5% or 4–6.7 mmol/L fasting and 8–10 mmol/L postprandial would reflect this goal[8].

Table 1 shows the corresponding equivalences of glycated haemoglobin values to that of fasting blood glucose and post prandial glucose values in mg/dL.

Table 1: Ranges of self-monitored blood glucose values for various Glycated haemoglobin goals [7]

<table>
<thead>
<tr>
<th>Glycated haemoglobin goal</th>
<th>Fasting blood glucose* (mg/dL)</th>
<th>Post-prandial blood glucose (mg/dL)</th>
<th>Average blood glucose** (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 6%</td>
<td>&lt; 100</td>
<td>&lt; 140</td>
<td>126</td>
</tr>
<tr>
<td>&lt; 7%</td>
<td>90-130</td>
<td>&lt;180</td>
<td>154</td>
</tr>
<tr>
<td>&lt; 8%</td>
<td>120-160</td>
<td>&lt;210</td>
<td>182</td>
</tr>
<tr>
<td>&lt; 9%</td>
<td>160-190</td>
<td>&lt;240</td>
<td>211</td>
</tr>
</tbody>
</table>

* It is not advised to achieve fasting sugars values targeted below 70 mg/dL.
** This mean uses both fasting and post-prandial blood sugar recordings from regular glucose monitors or from 7-point daily testing.

Overweight diabetic patients should be counselled on the need to maintain healthful eating pattern to promote weight loss. Patients should be given the necessary support in event of their weight loss program [8].

Poorly controlled high blood pressure is a crucial cardiovascular risk consideration that increases the advancement of diabetic nephropathy. Upon diagnosis of hypertension,
treatment should be started immediately with the aim of attaining blood pressure levels less than 140/90 mmHg[8]. A clinician should recommend moderate- or high-intensity statin therapy for all type 2 diabetics between the ages of 40-75 with a LDL ≥ 70 mg/dL[8].

Table 2 shows the equivalent values of average blood glucose measurements in mmol/L to that of HbA1c in percentage and mmol/mol.

**Table 2: Glycated haemoglobin and corresponding blood glucose levels**

<table>
<thead>
<tr>
<th>Glycated haemoglobin (%)</th>
<th>Glycated haemoglobin (mmol/mol)</th>
<th>Average blood glucose (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>119</td>
<td>18</td>
</tr>
<tr>
<td>12</td>
<td>108</td>
<td>17</td>
</tr>
<tr>
<td>11</td>
<td>97</td>
<td>15</td>
</tr>
<tr>
<td>10</td>
<td>86</td>
<td>13</td>
</tr>
<tr>
<td>9</td>
<td>75</td>
<td>12</td>
</tr>
<tr>
<td>8</td>
<td>64</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>53</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>42</td>
<td>7</td>
</tr>
</tbody>
</table>
2.6 CONCEPTUAL FRAMEWORK

Figure 1 shows the relationship between patient factors and health outcomes, and the association between self-care behaviours, access to primary care centre, standard treatment targets and improved health outcomes.

**Patient factors**
- Age
- Gender
- Education
- Employment
- Duration of disease
- Marital status
- Family History

**Self-care behaviours**
- Medication adherence
- Blood glucose monitoring
- Physical activity
- Health diet

**Access**
Having usual source of care and visits to the primary care centre.

**Process**
- HbA1c measurement
- Cholesterol measurement
- Blood pressure measurement
- Type of treatment offered (diet, oral medication, insulin)

**Clinical outcomes**
- Glycemic control, Lipid control, Blood pressure control
- Nephropathy
- Neuropathy
- Retinopathy
- Foot ulcers
- Amputation

Figure 1: Conceptual framework for determinants of quality of care in diabetic patients
CHAPTER THREE

3. METHODS

Two separate quantitative studies were conducted. The first was a retrospective audit of prescribing and monitoring practices. The second was a prospective survey of patient self care practices.

3.1 STUDY SITE

The study site was Vihiga County Referral Hospital, the largest public hospital in Vihiga County that is located along Kisumu-Kakamega Highway in Mbale town. The hospital has a bed capacity of 160 beds. According to Kenya County Data Sheets 2014, the county has an adult population of approximately 246,000 persons.

The study was carried out at the hospital registry office and at the medical outpatient clinic. The hospital registry office where the entire inpatient and outpatient records are stored is located in the first floor of the hospital building near the administration block and is under the control of a qualified health records officer in-charge.

The Medical outpatient clinic (MOPC) at the hospital is a physician based clinic designed to meet the needs of diabetics and hypertensives who require initial and continuing treatment and care. In addition to the physician, there is a complement of a multidisciplinary team of healthcare professionals who provide the required service at the clinic. The team serves the needs of patients who require follow up care, monthly check-ups or treatment for medical problems associated with diabetes and hypertension.

Vihiga County Referral Hospital is the most well equipped hospital in the region, with several specialist consultants and was selected for this study because majority of patients from the general community who are on therapy access care from this facility as their major primary care centre.
3.2 RETROSPECTIVE CROSS SECTIONAL AUDIT

3.2.1 Study design and Population

This was a retrospective descriptive audit of prescribing and monitoring practices. The study population comprised of Type 2 diabetes patients attending the medical outpatient clinic.

3.2.2 Inclusion and exclusion criteria for the clinical audit

Patient files included were those for patients who had type 2 diabetes as the primary diagnosis, attended routine MOPC between January and June, 2015 and were either male or female adults age 18 years and above.

Patient files for those patients with any other type of diabetes and attended MOPC with Hypertension as the primary diagnosis without diabetes were excluded from the study.

3.2.3 Sample size for the clinical audit

The Cochran formula [20] was used to calculate the sample size. The formula for the sample size is as presented in equation one. The calculated sample size was based on previous reported prevalence of how often practising physicians claim to use guidelines when treating patients. A study done in the United States estimated a prevalence 27% according to the New England Healthcare Institute[21].

\[
\text{Equation 1: } n = \frac{(Z^2 \times P(1-P))}{e^2}
\]

Where,

- \( Z \) = value from standard normal distribution corresponding to desired confidence level (\( Z=1.96 \) for 95% CI)
- \( P \) = expected true proportion
- \( e \) = desired precision.

Thus, the estimated sample size was 303 patient files.

Cochran’s finite population correction formula used to calculate the final sample size. The formula is presented in equation two:
Equation 2: \[ n = \frac{n_0}{1 + \frac{n_0}{\text{Population}}} \]

Where:

Population size = 709,
\( n_0 \) = Sample size according to Cochran’s formula = 303
\( n \) = Sample size

The sample size obtained after correcting for finite population was 212.

3.2.4 Sampling method

A systematic random sampling method was used to obtain the sample files. A list of the 709 type 2 diabetes patients who attended clinic from January 2015 to June 2015 was obtained. From the list, the researcher randomly selected the first sample element from the first 709 elements on the population list. Thereafter, every third element on the list was selected, where 3 is the appropriate sampling interval that allowed for the achievement of the target sample size. This was done until the calculated sample size of 212 was obtained.

3.2.5 Data collection

Data collection for this study phase was conducted on any other day of the week than the clinic day to minimize interruption of clinic activities. The sampled files were retrieved and data on the variables and outcomes of interest extracted. The data collection also included details on patient’s demographics. The data collected was entered into a predesigned data collection form (Appendix 1).

Review of the individual patient files was carried out to identify the cases that had been diagnosed and managed at the institution. In addition, records of patients who developed complication amongst the cases were noted. The individual recent recorded measurements of HbA1c/FBG/OGTT, blood pressure, cholesterol and weight/BMI recorded within the study period were also retrieved.
3.3 PROSPECTIVE PATIENT SURVEY

3.3.1 Study design and Population

This was a prospective descriptive survey of diabetic patients on self monitoring practices. The study population comprised of Type 2 diabetes patients attending the medical outpatient clinic.

3.3.2 Inclusion and exclusion criteria for the clinical audit

Participants included were those for patients who had type 2 diabetes as the primary diagnosis, attended routine MOPC between January and June, 2015 and were either male and female adults age 18 years and above. Similarly, those with outpatient booklets and gave voluntary consent were included.

Participants with any other type of diabetes and attended MOPC with Hypertension as the primary diagnosis without diabetes were excluded from the study.

3.3.3 Sample size

Because this was a pilot study, as sample size of 25 participants was used.

3.3.4 Sampling method

For every clinic day, approximately 50 clients were seen. This was usually conducted once in a week. The first client was approached, requested and if he/she accepted then were considered for recruitment. Upon completion of the interview with the client, the procedure was repeated on the next available clients until a sample of 5 participants was achieved per day. This was repeated on subsequent clinic days until the target sample size of 25 respondents was attained.

3.3.5 Participant recruitment and Data collection

The patient was approached at the pharmacy dispensing window after collecting their drugs and invited into the pharmacy office where he/she was briefed about the study and requested
to participate in it. Informed consent (Appendix 2) was sought and obtained prior to start of the administration of the questionnaire.

The structured questionnaire was administered by the researcher (data collection form Appendix 3). Information about participants’ medicine use, recent eating habits, physical activity and blood glucose testing was collected. In addition, socio-demographic data including age, sex, education, marital status, and employment was obtained, as well as their opinions regarding all these activities collected. Patients were then requested for their outpatient booklets that aided extraction patients’ personal demographic data. Data obtained was recorded in the data collection sheets (Appendix 2). The interview for those who consented lasted approximately 20-30 minutes.

3.4 DATA MANAGEMENT

To ensure confidentiality, unique patient identifiers rather than patient names or outpatient numbers were used in the data capture forms. All the data from retrieved files was extracted at the hospital registry office. Any document linking the collected data to the patient files or identity in hardcopy were kept under lock and key and was only accessible by the principal investigator. The soft copy raw data was password protected by the principal investigator. Data was entered in the Microsoft Excel worksheet 2010 and counterchecked for completeness and accuracy by the principal investigator on the same day of data entry.

3.5 QUALITY ASSURANCE

The data collection form (questionnaire, Appendix 3) was pre-tested on a pilot sample of five patients, to estimate the time needed for the administration and assess the clarity and suitability of the questions. Accordingly, modifications were done to make the questions shorter, clearer and easier to understand. This pilot sample was excluded from the study sample.

3.5.1 STUDY VARIABLES

The primary outcome variable was adherence by health care workers to the ICSI guideline for management of diabetes. The outcome was measured using the following indicators: the
cases diagnosed, managed and monitored in accordance with ICSI treatment guidelines, proportions of patient who attained treatment targets.

The secondary objective of the study was to relate the presence of complications with attainment of therapeutic targets and socio-demographics characteristic of the patients. For this analysis, the main outcome of interest was presence of any complication which included retinopathy and neuropathy. The independent variables that are known risk factors for these complications include age, gender, cadre, blood glucose, blood pressure, duration of disease, methods of diagnosis, and prescribed drug therapy for diabetes. The achievement of standard treatment targets for HbA1c, FBG, OGTT, RBS, blood pressure, cholesterol and weight/BMI was also used as independent variables.

3.6 DATA ANALYSIS

The collected data was entered to IBM SPSS\textsuperscript{R} Statistics version 22 database. P-P normality plots were generated to determine if the continuos were normally distributed. The continuous variables were summarised as means and the standard deviation of the mean if they were normally distributed. Continuous variable that were not normally distributed were summarised as the median and interquartile range. Categorical data was summarised as proportions. The results were expressed graphically.

Inferential data analysis was done using the Student t-test, chi square test and the Mann Whitney non parametric tests. Bivariable analysis was used to determine any relationship between compliance to diagnosis and management as per ICSI treatment guidelines and the other variables under study. Odds ratios with 95% confidence interval were computed.

Binary logistic regression was conducted to identify risk factors of diabetic complications. Model building to come up with a parsimonious model was done using forward stepwise model building. All variables that were significant on the bivariant logistic regression were considered for the model building. The level of significance was set at 0.05.
3.7 ETHICAL CONSIDERATIONS

Ethical approval was sought and obtained from the KNH-UoN Ethics and Research Committee (P641/10/2015) as study involved human subjects and identifiable health information data was accessed. See Appendix 4.

Informed consent was sought from the anticipated participants in the survey, prior to data collection. The informed consent form (Appendix 2) was used for this purpose. Study tools and the consent process information and form were translated from English version to Kiswahili version to facilitate comprehension.

Patient records were anonymised and any patient identifiers removed to assure confidentiality of patient information (See section 3.6) Participants were informed that they were free to leave the study at any time without having to give any reason. Any withdrawal from the study would not jeopardize their access to their usual services at the hospital.

There was no compensation in this study. Patients were informed that they are likely to benefit from future interventions that may improve practices of care and treatment being offered at the facility. Any case encountered that required further management was referred back to the physician in-charge.
CHAPTER FOUR

4. RESULTS

4.1 RETROSPECTIVE CROSS SECTIONAL AUDIT OF COMPLIANCE TO TREATMENT GUIDELINES

A total of 212 patient files were retrieved and data on patient’s demographics and information on compliance to ICSI treatment guidelines obtained and captured in the data collection form.

4.1.1 Patient demographics and clinical characteristics

The largest proportion of the participants were aged between 50 – 59 years (31.1%) with majority female (70.3%). Duration of illness was between 1 to 5 years in 39.6% of the respondents. However, information on duration of illness was available for 54.3% (115) of the respondents. Table 3 presents a summary of the patient demographic characteristics.

Table 3: Distribution of patients as per the Age, sex and duration of illness

<table>
<thead>
<tr>
<th>Demographics</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 - 29</td>
<td>4</td>
<td>1.9</td>
</tr>
<tr>
<td>30 - 39</td>
<td>7</td>
<td>3.3</td>
</tr>
<tr>
<td>40 - 49</td>
<td>23</td>
<td>10.8</td>
</tr>
<tr>
<td>50 - 59</td>
<td>66</td>
<td>31.1</td>
</tr>
<tr>
<td>60 - 69</td>
<td>63</td>
<td>29.7</td>
</tr>
<tr>
<td>70 - 79</td>
<td>41</td>
<td>19.3</td>
</tr>
<tr>
<td>≥80 years</td>
<td>8</td>
<td>3.8</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>63</td>
<td>29.7</td>
</tr>
<tr>
<td>Female</td>
<td>149</td>
<td>70.3</td>
</tr>
<tr>
<td><strong>Duration of Illness (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5</td>
<td>84</td>
<td>39.6</td>
</tr>
<tr>
<td>6 - 10</td>
<td>16</td>
<td>7.5</td>
</tr>
<tr>
<td>11 - 15</td>
<td>12</td>
<td>5.7</td>
</tr>
<tr>
<td>16 - 20</td>
<td>1</td>
<td>.5</td>
</tr>
<tr>
<td>≥21</td>
<td>2</td>
<td>.9</td>
</tr>
<tr>
<td>Not indicated</td>
<td>97</td>
<td>45.8</td>
</tr>
</tbody>
</table>
For those participants whose duration of illness was reported, analysis showed that majority of those who had the disease for duration of 6 years and above were aged 50 years and above.

4.1.2 Prescriber information

The respondents had been attended to by various cadres of healthcare personnel within the health facility at the time of diabetes diagnosis. A greater majority had their illness diagnosed by a medical officer (48.1%) while medical officers on internship diagnosed 22.2% of the patients. Only 1 of the respondents had their condition diagnosed by a Registered Clinical Officer. Prescriber information was unavailable in 9% of the patient files as depicted in

![Figure 2: Healthcare providers at initiation of therapy]

4.1.3 Compliance to guidelines on diagnosis, drug selection and monitoring of diabetes

Table 4 summarises the rates of the compliance treatment guideline by Health care workers. Each the key indicators will be described.
### Table 4: Compliance to guidelines on diagnosis, management and monitoring of diabetic therapy

<table>
<thead>
<tr>
<th>METHOD OF DIAGNOSIS</th>
<th>COMPLIANCE RATE</th>
<th>COMMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random Blood Sugar</td>
<td>58.5%</td>
<td>There was good compliance</td>
</tr>
<tr>
<td>Fasting Blood Glucose</td>
<td>34.0%</td>
<td></td>
</tr>
<tr>
<td>Glycated Haemoglobin</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>No test indicated</td>
<td>6.5%</td>
<td></td>
</tr>
</tbody>
</table>

#### DRUGS USED AT INITIATION

<table>
<thead>
<tr>
<th>DRUGS USED AT INITIATION</th>
<th>COMPLIANCE RATE</th>
<th>COMMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>15.6%</td>
<td>There was good compliance</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>8.5%</td>
<td>although patients should be initiated on metformin alone before combining with other antidiabetics.</td>
</tr>
<tr>
<td>Metformin and Glibenclamide</td>
<td>56.6%</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>12.3%</td>
<td></td>
</tr>
</tbody>
</table>

#### TESTS DONE AT INITIATION

<table>
<thead>
<tr>
<th>TESTS DONE AT INITIATION</th>
<th>COMPLIANCE RATE</th>
<th>COMMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure checked</td>
<td>96.7%</td>
<td>Non compliance with monitoring cholesterol and weight was very high</td>
</tr>
<tr>
<td>Cholesterol levels checked</td>
<td>6.1%</td>
<td></td>
</tr>
<tr>
<td>Weight measurement</td>
<td>1.4%</td>
<td></td>
</tr>
</tbody>
</table>

#### BLOOD GLUCOSE TESTS DONE ON FOLLOW UP

<table>
<thead>
<tr>
<th>BLOOD GLUCOSE TESTS DONE ON FOLLOW UP</th>
<th>COMPLIANCE RATE</th>
<th>COMMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Blood Glucose</td>
<td>66.5%</td>
<td>The use of Random blood sugar test in not recommended on follow up thus being non compliant.</td>
</tr>
<tr>
<td>Random Blood sugar</td>
<td>31.6%</td>
<td></td>
</tr>
<tr>
<td>Glycated Haemoglobin</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Not indicated</td>
<td>1.9%</td>
<td></td>
</tr>
</tbody>
</table>

#### Method of diagnosis and medication selection at treatment initiation

The ICSI guidelines recommend that diagnosis should be based on measurements of glycated haemoglobin (HbA1c), Fasting Blood Glucose (FBG) and Random Blood Sugar (RBS) [8]. Measurements of RBS was the most used method of diagnosis with 58.5% of the patients having been diagnosed using this method. The FBG test was used in 34% of the respondents. Only 1% of the patients were diagnosed using HbA1c tests while 6.5% patients lacked details on method of diagnosis (Table 4). The ICSI treatment guidelines
recommend that patients on follow up be monitored for their blood sugar levels using Hb1Ac or FBG test [8]. The use of RBS is not explicitly recommended for monitoring of blood sugar levels by the guidelines.

A majority of the participants (66.5%) had their blood sugar monitored using the FBG test compared to those using RBS (31.6%); none were monitored using Hb1Ac. Some 1.9% of patients’ records had no details on blood sugar monitoring. Table 4 depicts the use of different types of blood sugar tests for monitoring treatment targets.

The ICSI treatment guidelines recommend that patients with Type 2 diabetes mellitus should be initiated on metformin as first-line pharmacotherapy, or metformin in combination with other glucose-lowering agents, unless medically contraindicated[8].

Participants were initiated on different kinds of medications as either monotherapy or dual therapy. Monotherapy medications were metformin, glibenclamide, gliclazide, chloropropamide or insulin. Metformin with glibenclamide or insulin with glibenclamide combinations were used as dual therapy. About 57% of patients were initiated on metformin in a combination therapy while 15.6% were on metformin alone as their first line therapy. Table 4 details the drugs at initiation of treatment for the respondents.

4.1.5 Blood pressure, cholesterol and weight monitoring at initiation

The ICSI treatment guidelines recommend that a protocol should in detail set out the indicators to be checked at first visit, routine follow-up visits, and at the periodic yearly review[7]. In this case, individual patient risk assessment should be carried out for blood pressure, cholesterol levels and weight at initial visit[8].

Based on the patient records, almost all the patients (96.7%) had their blood pressure checked. Only 6.1% of the patients had their cholesterol levels checked and even fewer, (1.4%) had their weight measurements taken. Table 4 presents the findings.
4.1.6 Monitoring and Attainment of treatment therapeutic targets for Sugar, Blood pressure, lipid levels, weight and renal function on follow up

Table 5 summarises follow up therapeutic treatment targets for the participants.

Table 5: Attainment of treatment targets on follow up between January and June, 2015

<table>
<thead>
<tr>
<th>PARAMETER</th>
<th>THRESHOLD VALUE</th>
<th>% WITHIN TARGETS RANGE</th>
<th>% OUTSIDE TARGET RANGE</th>
<th>MEAN (SD) (^1) or MEDIAN (IQR) (^2) VALUES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Have hypertension</td>
<td>-</td>
<td>188 (97.2%)</td>
<td>24 (2.8%)</td>
<td>-</td>
</tr>
<tr>
<td>Controlled systolic blood pressure (mmHg)</td>
<td>140 mmHg</td>
<td>110 (51.1%)</td>
<td>92 (48.9%)</td>
<td>139.56 ±20.94 mmHg (^a)</td>
</tr>
<tr>
<td>Controlled diastolic blood pressure</td>
<td>90 mmHg</td>
<td>186 (86.2%)</td>
<td>26 (13.8%)</td>
<td>79.81 ±11.03 mmHg (^b)</td>
</tr>
<tr>
<td>Fasting blood glucose test (n=141)</td>
<td>7 mmol/L</td>
<td>28 (20%)</td>
<td>113 (80%)</td>
<td>8.9 (IQR 7.40 to 12.75 mmol/L (^c))</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>-</td>
<td>No records</td>
<td>No records</td>
<td>-</td>
</tr>
<tr>
<td>Weight</td>
<td>-</td>
<td>No records</td>
<td>No records</td>
<td>-</td>
</tr>
<tr>
<td>Renal function tests</td>
<td>-</td>
<td>No records</td>
<td>No records</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^a\) The mean systolic blood pressure was not statistically higher than the target (p=0.638)
\(^b\) The mean diastolic blood pressure was not statistically higher than the target (p=0.000)
\(^c\) The median fasting glucose was not statistically higher than the target (p=0.741)
\(^1\) Standard deviation
\(^2\) Interquartile ranges

The median blood sugar for all the participants tested with FBG was 8.9 (IQR 7.40, 12.75) mmol/L (Table 5). Amongst the 141 participants tested using the FBG, 80% did not have their blood sugars controlled adequately as per the guidelines. The guidelines recommend that the blood sugars should be maintained below 7 mmol/L. The median blood sugar for the participants tested with FBG was compared against the threshold value (7 mmol/L) to find out if they were significantly higher than this recommended threshold. The independent sample Mann Whitney result showed the median blood sugar was not significantly higher than the target threshold of 7 mmol/L (p=741),(Table 5).

Blood pressure monitoring data was available for the 212 patients. Overall, the mean systolic blood pressure for these patients was 139.56±20.94 mmHg while mean diastolic blood pressure was 79.81±11.03 mmHg during this follow up period. Amongst the 212 patients
with follow-up blood pressure monitoring data, 188 (97.2%) had hypertension as comorbidity and were on antihypertensive treatment.

The ICSI guidelines recommend that diabetics with a blood pressure \( \geq 140/90 \) mmHg should be started on antihypertensive therapy and blood pressure should be maintained below these levels.

The mean systolic blood pressure (139.56±20.94 mmHg) was compared against the recommended threshold value (140 mmHg). Results show it was not significantly higher than the target maximum value (p=0.638). Similarly, the mean systolic blood pressure (79.81±11.03 mmHg) was compared against the recommended threshold value (90 mmHg) and this was found to be significantly higher than the target maximum value (p=0.000).

4.1.6.1 Cholesterol levels, weight, BMI and renal function tests on follow up

Only 6 (2.8%) patients had their cholesterol levels checked and recorded during the follow-up study period. None of the patients had their weight nor BMI recorded during follow up. Of the 2.8% whose cholesterol levels were taken, there was incomplete information regarding the test values and corresponding reference values. It was only indicated as high or normal. Those indicated as normal were five whilst one was high. There was no evidence of renal function tests request or results forms in all the patient files reviewed.

4.3 PREVALENCE AND RISK FACTORS FOR COMPLICATIONS ASSOCIATED WITH TYPE 2 DIABETES

The proportions of participants presenting with various microvascular complications are as presented in Figure 3. The most common complication experienced by the patients was neuropathy (41%) followed by retinopathy (33%). The least frequent complication was nephropathy in only 0.9% of the patients. Under-reporting of nephropathy may be attributed to lack of records on renal function tests that would have ascertained the presence of nephropathy. The patients were also checked for foot ulcers and amputations.
4.3.1 **Risk factors of Retinopathy**

Table 6 presents the findings of logistic regression analysis to identify determinants for retinopathy.

**Table 6: Summary of the risk factors for retinopathy**

<table>
<thead>
<tr>
<th>Variable on follow up</th>
<th>Crude odds ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at initiation</td>
<td>1.011 (1.007, 1.016)</td>
<td>0.000</td>
</tr>
<tr>
<td>Female Gender</td>
<td>1.577 (1.331, 1.866)</td>
<td>0.000</td>
</tr>
<tr>
<td>Cadre</td>
<td>1.223 (1.118, 1.338)</td>
<td>0.001</td>
</tr>
<tr>
<td>Duration of illness (n=113)</td>
<td>1.072 (1.005, 1.114)</td>
<td>0.034</td>
</tr>
<tr>
<td>Blood pressure at initiation</td>
<td>2.44 (1.545, 2.703)</td>
<td>0.000</td>
</tr>
<tr>
<td>Method used for diagnosis</td>
<td>1.234 (1.135, 1.341)</td>
<td>0.000</td>
</tr>
<tr>
<td>Antidiabetic drugs initiated</td>
<td>1.228 (1.118, 1.349)</td>
<td>0.000</td>
</tr>
<tr>
<td>Controlled Systolic pressure</td>
<td>1.744 (1.199, 2.538)</td>
<td>0.004</td>
</tr>
<tr>
<td>Controlled Diastolic pressure</td>
<td>2.889 (1.354, 6.165)</td>
<td>0.006</td>
</tr>
<tr>
<td>Fasting blood glucose test (n=141)</td>
<td>2.382 (1.596, 3.556)</td>
<td>0.000</td>
</tr>
<tr>
<td>Random blood sugar (n=64)</td>
<td>1.500 (0.674, 3.339)</td>
<td>0.321</td>
</tr>
</tbody>
</table>
For the known risk factors assessed, all were positively associated with retinopathy (Table 6). Females had higher risk compared to males’ crude OR 1.577 (95% CI 1.331, 1.866). As expected, increase in age increased the risk of retinopathy. Participants who had their blood pressure taken at initiation had an increased risk of having retinopathy. Participants initiated on metformin had lowest prevalence of retinopathy at 21%. On the other hand, 40% initiated on glibenclamide developed retinopathy. These findings seem to suggest that initiating patients on metformin reduces the risk of retinopathy while patients initiated on sulphonylureas had high risk of retinopathy. Patients initiated on combined therapy of glibenclamide and metformin also had higher risk compared to those on metformin alone. There was no statistically significant association between systolic blood pressure and retinopathy while on other hand there was a statistically significant association with well controlled diastolic blood pressure and retinopathy. This seems to suggest that it is more important to control diastolic blood pressure as opposed to systolic blood pressure to prevent retinopathy. The only variable not associated with retinopathy was the controlled random blood sugars at follow up. Patients with poorly controlled fasting blood glucose on follow up had a two-fold odd of developing retinopathy compared to those with well controlled fasting blood glucose levels (Table 6). On model building, having high blood pressure was the most significant predictors of retinopathy.

4.3.2 Risk factors for neuropathy

Unlike retinopathy, gender was not a risk factor for neuropathy (Table 7). Similarly, increased duration of illness did not increase the risk of neuropathy. Uncontrolled Systolic blood pressure was positively associated with neuropathy unlike uncontrolled diastolic blood pressure that was not associated with neuropathy.

As seen previously in the case of retinopathy, well controlled random blood sugars had no association with neuropathy. Before adjusting for confounding, there was a very weak association between fasting blood glucose and neuropathy, although it was almost significant (p=0.078) (Table 7). On model building, fasting blood glucose was the most powerful predictor of neuropathy compared to other variables, adjusted odds ratio 1.018 (95 C.I 1.006, 1.029)

Patients on insulin had the lowest prevalence of neuropathy at 27%. The risk of neuropathy in those on metformin was 33%. Those initiated on combined therapy of glibenclamide and
metformin had prevalence 47%. This seems to suggest that patients treated with sulphonylureas may have a higher risk of neuropathy. The effect of drug therapy was significant when adjusting for confounding crude OR 1.228 (95% CI 1.096, 1.370). It lost significance when adjusted for confounding by systolic blood pressure, adjusted OR 0.839 (95% C.I. 0.714, 1.116)

Table 7: Summary of risk factors to neuropathy

<table>
<thead>
<tr>
<th>Variable on follow up</th>
<th>Crude odds ratio (standard deviation)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.005 (1.000, 1.009)</td>
<td>0.040</td>
</tr>
<tr>
<td>Female Gender</td>
<td>1.087 (0.952, 1.241)</td>
<td>0.217</td>
</tr>
<tr>
<td>Cadre</td>
<td>1.126 (1.035, 1.226)</td>
<td>0.006</td>
</tr>
<tr>
<td>Duration of illness (n=113)</td>
<td>1.27 (0.970, 1.088)</td>
<td>0.363</td>
</tr>
<tr>
<td>Blood pressure at initiation</td>
<td>1.449 (1.112, 1.887)</td>
<td>0.006</td>
</tr>
<tr>
<td>Method used for diagnosis</td>
<td>1.112 (1.028,1.203)</td>
<td>0.008</td>
</tr>
<tr>
<td>Antidiabetic drug initiated on.</td>
<td>1.079 (0.988, 1.178)</td>
<td>0.090</td>
</tr>
<tr>
<td>Controlled systolic levels</td>
<td>1.744 (1.199, 2.538)</td>
<td>0.004</td>
</tr>
<tr>
<td>Controlled diastolic levels</td>
<td>1.059 (.0546, 2.054)</td>
<td>0.866</td>
</tr>
<tr>
<td>Fasting blood glucose test (n=141)</td>
<td>1.396 (0.964, 2.022)</td>
<td>0.078</td>
</tr>
<tr>
<td>Random blood sugar test (n=64)</td>
<td>0.923 (0.421, 2.023)</td>
<td>0.842</td>
</tr>
</tbody>
</table>
4.4 PROSPECTIVE SURVEY OF PARTICIPANTS ON SELF-CARE BEHAVIOURS IN TYPE TWO DIABETES

4.4.1 Patient demographic characteristics

A total of 25 patients were interviewed and their responses were received and analysed for perceptions regarding diabetes and its management. Slightly more than half of the participants were male (52%). Most of them were unemployed (88%) and almost all were married (92%). Most of the respondents had secondary level of education (41.7%). Slightly less than half of the respondents had family history of diabetes (40%). The mean age of the participants was 58.36 years with a range of 37 to 81 years while their mean weight was 78.5 kgs with a range of 42 to 111 kgs.

4.4.2 Participant perceived adequacy of glycemic control

Patients were asked how satisfied they were with their overall blood glucose control. Approximately half of the respondents (52%) considered themselves to have good control of their glucose levels; 8% claimed they had very good control, while 12% had excellent satisfaction with their glucose control. However, 28% were experiencing problems with glucose control.

Majority of the respondents (68%) maintained the targeted range for their blood glucose as agreed upon with their doctor compared to 32% who were not cautious on maintaining a target range. The blood sugar levels for most of the respondents (68%) were never too high whilst 28% had high blood sugars occasionally a month. On the other hand, the blood sugar for 84% of the respondents was never too low whilst 12% had low blood sugars occasionally a month. Figure 4 summarises patients’ perception of blood glucose control.
4.4.3 Knowledge and practice of dietary control of diabetes

Patients were asked about their eating habits. All the respondents reported using sugar free products at least one or more times a day. Most of the respondents (80%) reported to never having used information on calories, carbohydrates or fat content in food labels to make decisions on what food to eat. Amongst the respondents, 56% reported to never have skipped a meal deliberately in order to reduce on calories or fat while 24% reported to skip meals at least one or more times a day. Amongst the respondents, 60% knowingly took less portions of food to cut on calories, while 24% never considered taking small portions of food at all. Regarding the use of a written meal plan to know what foods to eat, 64% reported to use it one or more times a day while 28% never used it. Figure 5 presents the findings.
Participants were asked about overeating, unplanned snacking, or poor food choices. Majority of the respondents reported to never have had any problem with diet. However, 14% reported to have had eating problems because of hunger or craving for specific foods at least one to two times a week while another 14% had hunger or craving for specific foods once a month. Another 13 and 9% had eating problems once a month and at least one or more times per day respectively, because either family or some friends did not support them in the efforts to eat right (Figure 6).
Patients were asked about their use of medication to treat diabetes. About 88% of respondents had their antidiabetic tablets at the time of the interview. About 72% were taking their tablets twice a day, while 16% took them three times daily. The proportion of respondents on insulin was 17%. All of these respondents were injecting insulin twice a day. None of these respondents reported to ever miss taking a dose of either the tablets or insulin shots.

Participants’ opinions were sought on barriers to taking medications (either tablets or insulin shot). Most expected barriers such as cost and low mood or depression did not have much influence on medication use as shown in Figure 7. Only 12% of the respondents stated that low mood and cost of medicines were barriers to adherence once per month. Lack of support from family and friends hindered 8% from effectively taking their medication (see Figure 7).
Figure 7: Factors hindering effective medication use.

4.4.7 Participant blood glucose monitoring practices

Respondents’ opinions were also sought on patterns of testing their blood glucose levels. Amongst the respondents, 48% had not been told to test their blood glucose while 20 and 24% were told to test occasionally as needed and one or two times a week respectively.

Majority of the respondents (68%) tested their blood glucose only on their clinic appointment days. Another 20% tested their blood sugars more frequently than this, with 8% testing their level at least once a day. One respondent tested his blood sugar three or four times a day.

Most of the expected barriers (depression, hates pricking, lack of social support, busy schedules) did not seem to hinder respondents from monitoring their blood glucose. The most important barrier to glucose monitoring was the cost of supplies. Nine (36%), of the respondents felt that the cost of blood sugar monitoring machines and supplies was a key barrier.
4.4.8 Engaging in routine physical activity

Respondents were asked about the levels of physical activity they engaged in. Twenty (80%) respondents had been advised by their doctor to exercise while 5(20%) did not receive any advice.

Respondents were asked the extent of physical activity they benefit from as a result of routine work like going on shopping, performing housework, engaging in yard work or other daily activities. Amongst them, 18(76%) were very active while 4(16%) were inactive. Nearly all, 23(92%), engaged in activities like walking, running, cycling at least once a day, or more. None of them were going to the gym or participating in sports.

4.4.9 Factors hindering participants from engaging in exercises

Participants’ responses were sought on why it was difficult to begin exercising or abide by an exercise schedule. Many (24%) claimed that exercise and physical activity caused pain and discomfort once or twice week. A smaller number (12%) claimed that exercise caused and discomfort twice or thrice a month). Majority of them, (56%) reported that pain and discomfort was as a barrier. Generally, most of the other expected the barriers (depression, lack of social support, when away for vacation, preoccupied with other responsibilities) did not seem to cause a problem in respondents executing physical activities.

4.4.10 Overall assessment on patient self care behaviour

Generally, it was observed that medication use and engagement with physical activity were well adhered to with least number of barriers appearing to hinder participants from effectively executing these two activities. Problems were observed with dietary knowledge and practices because some patients never understood the importance of obtaining or following a prescribed meal plan. Self-monitoring of blood glucose levels was not evident because most of the patients had their blood sugar tests done only at the hospital with majority indicating lack of testing supplies as hindrance to frequent monitoring of their sugar levels.
CHAPTER FIVE

5. DISCUSSION

From the findings, patients were diagnosed according to the recommendation of the ISCI treatment guidelines with regards to the diagnostic methods used in testing for blood glucose levels. Random Blood Sugar and FBG were the most commonly used methods of diagnosis compared to HbA1c. This can be attributed to unavailability of technical resources (laboratory testing materials and equipment) and inadequate financial resources necessary to support the use of HbA1c as a primary diagnostic procedure at the facility[7]. A study on laboratory medicine in Africa indicated that allocation of resources to diagnostic laboratory testing has not been a priority for resource-limited health care systems. In addition, unreliable and inaccurate laboratory diagnostic testing leads to unnecessary expenditures [22]. Compared to FBG, OGTT and RBS tests, glycated haemoglobin (HbA1c) test is the most preferable for measuring blood glucose levels because it detects long term glucose vulnerability over a period of two to three months. It also is less affected by internal considerations like anxiety or illness [8]. Nonetheless, adherence to guidelines with regards to diagnosis of diabetes was followed, which was a positive impact on practise by clinicians.

Oral drug therapy is a preferred when one’s glucose targets are not achieved by both diet modifications and vigorous exercise. Metformin is the ICSI guidelines’ first line oral pharmacotherapy recommendation and most of the diabetic patients were initiated either on metformin as single therapy or in combination with other hypoglycaemic drugs. A satisfactory compliance of 72% to the ICSI guidelines with regards to first line therapy use of metformin was achieved, though there is much room for improvement. Non-compliance to these guidelines recommendations’ may lead to suboptimal therapeutic goals and also associated with increased risk of hospitalization of diabetic patients due to complications.

Early detection and prevention of complications are secondary preventive measures of diabetes. Similarly, early monitoring of blood pressure, cholesterol levels and weight measurements in management of diabetes enhances individuals’ quality of life. Type 2 diabetes frequently occur simultaneously with hypertension, obesity and dyslipidaemias whereby the occurrence of all three of these components in a type 2 diabetic patient constitute of metabolic syndrome[7]. Almost all the patients were monitored for their blood pressure levels and it was discovered that 89% were hypertensive. These findings are consistent with other studies which indicate that diabetes and hypertension coexist in approximately 40 to
60% of patients with type 2 diabetes. In addition, diabetics subjects have a 1.5 – 3 times increased prevalence of hypertension compared to non-diabetics, with 50% of adults with diabetes having hypertension at the time of diagnosis[23].

Obesity is a vital element of the metabolic syndrome. It is evaluated through measurement of weight and height that’s used to calculate the BMI of an individual. Monitoring of neither BMI nor weight measurements were rarely being done contrary to the recommendation by the ICSI treatment guidelines that indicates all patients’ weight and BMI should be monitored. Literature suggests that over 70% of Type 2 diabetics are either overweight or obese[7]. Due to this inconsistency in taking weight measurements, it was not clear what proportions of patients had excess weight or were obese. Having excess weight or being obese can drastically increase the risk of morbidity and death from Type 2 diabetes and its co-morbidities.

For those patients with some degree of dyslipidaemia, the dangers of developing coronary artery disease and other macro-vascular complications is 2 to 5 times higher in diabetics compared to those without diabetes [7]. Measurement of fasting lipids should be done annually if lipids levels are normal whilst every 3-6 months if abnormal or on treatment. Over the study period, it was noted that very few patients had their lipid profile measured. The data obtained was not sufficient to ascertain extent of dyslipidaemia amongst these patients. Therefore, inconsistent follow up on lipids levels would expose the patients to higher risks of mortality and morbidity due to complications associated with diabetes.

The ICSI treatment guidelines recommend HbA1c, FBG and post prandial glucose tests as ideal methods of follow up glycaemic control. The treatment guideline was not adhered to because not all patients were monitored for their blood glucose levels as per the recommendation. Almost 32% of the patients were monitored using RBS test. Random blood sugar test is only recommended for purposes of diagnosis. Random blood sugar test might have been used as an alternative monitoring test rather than FBG because the patients had probably taken a meal in between the fasting period of six to eight hours required before performing FBG test. For the 67% of patients who were tested with FBG test on follow up, 80% did not have their blood sugar levels controlled adequately. The benefits of achieving near-normal glycaemic control can lower the risk of diabetes micro-vascular complications such as retinopathy, nephropathy and amputations.
Low rates of nephropathy (1%) reported may be attributed to unavailability of laboratory resources for screening nephropathy, negligence by the clinician to request for some specific tests to be done or lack of skills and knowledge by the clinicians in treating diabetic patients. The prevalence of neuropathy (41%) and retinopathy (33%) are comparable to that of a study done in Malawi which revealed micro-vascular complications as being common with prevalence of retinopathy (34.7%), neuropathy (46.4%) and nephropathy (34.7%). This shows the risk of type 2 diabetic patients developing these micro-vascular complications[24].

Diabetic self-care activities are undertaken in order to successfully manage the condition. The activities assessed included healthy eating, being physically active, personal-monitoring of blood sugar levels and adherence to medication.

Majority of participants were not keen on specific information on quantity of calories, carbohydrates and fat that was contained in the food they consumed. These findings may be attributed to individuals’ ignorance, lack of knowledge/awareness or age factor since majority of the participants were elderly. This may result to patients consuming particular food nutrients in excess of what is required of them to adequately control the levels of sugars and calories. However, some studies have revealed controversy that surrounds the optimal ratio of carbohydrate-to-fat in the diet with respect to the prevention of type 2 diabetes. The association between dietary fat consumption and the proportion of the overweight population was positive. This therefore supports the notion of a reduced fat with increased carbohydrate intake as a preventative measure for chronic diseases[25]. Findings also showed that majority of the participants avoided binge eating which is characterised by exorbitant consumption of food without purging. Avoiding binge eating reduces the chances of developing obesity. Majority of the participants alluded to using a written diabetic meal plan which is a positive attribute and a good idea for diabetic patients. To promote adherence, a diabetic written meal plan should fit in an individual’s schedule and eating habits because the meal plan helps patients in determining how much to eat and what kinds of food one can choose to eat at meals and snack time.

The self-reported adherence to the use of medication amongst the participants in this study, either on twice a day regimen or three times a day regimen was 100%. Contrary to the findings, several studies compared cohorts with different medication adherence regimen and found that once a day regimen had higher rates of adherence than twice a day regimen (61%
High medication adherence observed could be attributed to patients’ positive attitudes and beliefs about the benefits of use of diabetes medications in the improvement of quality of life. Findings also revealed that the cost of medication and depression were major barriers to the use of medication. This is consistent with other studies that indicate that cost of treatment may be a significant barrier to diabetes treatment particularly for patients with low socioeconomic status and limited to no health insurance cover [26].

Self-monitoring of glycaemic control is considered the cornerstone of diabetes care that can ensure patient participations in achieving and maintaining specific glycaemic targets. On the contrary, it was observed that very few participants practised personal tracking of blood sugar levels. Majority of the participants’ blood glucose tests were carried out only at the hospital during the clinic appointment days that’s scheduled at a frequency interval of two to three months. This observation may be attributed to the lack of knowledge or awareness by participants on the importance of self-monitoring of glucose levels in management of the disease. On the contrary, evidence suggest that type 2 diabetic patients not on insulin therapy do not benefit clinically from self-monitoring of blood sugar. Decreased incidences of hospital admissions and morbidity are amongst the positive effects of self-monitoring of blood glucose levels[27], whereas negative results include no improvement in glycaemic control especially if the glycaemic control is not well sustained.

Majority of participants reported to actively engage in exercises like aerobic exercises that included walking, running, cycling and little of resistance exercise like yard work or housework. Engaging in either resistance or aerobic exercises reduces body fat and improves weight control, improves glucose tolerance, reduces insulin resistance, lowers resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in people with high BP amongst other benefits. A few of them reported pain and discomfort as a major barrier in executing physical activity.

The findings can be generalized to other primary care facilities which offer the same services in rural set up. The limitations which included poor quality of documentation in records that may have resulted in under reporting (or over-reporting) of treatment target indicators and presence of severe complications associated with diabetes. Also, a few prospective participants may have opted to leave the facility after doctors’ consultation without passing through the pharmacy for issuance of drugs. This might have created bias in data (for example clients who obtain medicines outside the hospital pharmacy did not have the opportunity to be interviewed) collected in the qualitative arm of the study.
CHAPTER SIX

6. CONCLUSION AND RECOMMENDATIONS

6.1 Conclusion

There were low levels of adherence to the following ICSI treatment recommendations: monitoring of weight, renal function, lipid levels and fasting blood sugar level. A few patients were wrongly initiated on sulphonylyureas. There was lack of adequate laboratory supplies that aid diagnosis and monitoring. There was high prevalence of retinopathy and neuropathy. Eighty percent of the participants did not achieve the targeted fasting blood glucose levels. Uncontrolled hypertension and fasting glucose levels were significant risk factors for complications. Patients lack on knowledge on nutritional interventions. Hence there is need to strengthen capacity to manage type 2 diabetes in this facility.

6.2 Recommendations

6.2.1 Recommendation for practice

There is need to either re-orient or train healthcare providers at Vihiga county referral hospital on the importance and use of diabetes clinical treatment guidelines as well as adherence to these guidelines in practice are emphasised.

The hospital administration can avail and adopt a health information technology system that will aid electronic medical recording and e-prescribing with a component of a prescribed diabetic-specific outpatient form inclusive. The system will enable healthcare providers readily access the guidelines at the point of care, keep track of complete individual patient history and offer support for clinical decision making.

There is need for the hospital administration to provide adequate resources to support the health information system technology adoption, healthcare provider training and maintenance of the information technology systems.
6.2.2 Recommendation for future research

Further studies can be done on exploration of factors affecting adherence to clinical treatment guidelines by healthcare providers’ in Vihiga County.

A study is needed to find out if the use sulphonylureas may increase the risk of neuropathy and retinopathy.
REFERENCES


11. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of Exercise on Glycemic Control and Body Mass in Type 2 Diabetes Mellitus A Meta-analysis of
Controlled Clinical Trials. 2008;286(10):11–5.


21. Hope Kenefick, Jason Lee, Valerie Fleishman: Improving Physician Adherence to
Clinical Practice Guidelines; Barriers and Strategies for Change. 2008;63.


APPENDIX 1: DATA COLLECTION FORM FOR PATIENT'S DEMOGRAPHICS AND INFORMATION ON COMPLIANCE TO ICSI TREATMENT GUIDELINES

STUDY TITLE: COMPLIANCE WITH GUIDELINES AND THE ROLE OF PATIENTS IN MANAGEMENT OF TYPE 2 DIABETIC PATIENTS AT VIHIGA COUNTY REFERRAL HOSPITAL, KENYA.

Serial Number_________ Date of Collection_____________ Version: 01 AUGUST 2015

A. BIODATA
1. Patient initials:_____________
2. Age:_____________
3. Gender: Male □ Female □
4. Marital status: Married □ Single □ Widowed □ Divorced □ Not Indicated □
5. Employment: Employed □ Self-employed □ Not indicated □

B. PRESCRIBER INFORMATION AT INITIATION
6. Cadre: Physician □ Medical Officer □ Medical Officer Intern □ Registered Clinical Officer □ Clinical Officer Intern □ Not Indicated □

C. PATIENT MEDICAL RECORD ON DIAGNOSIS
7. Date of first diagnosis: □_____________ □ Not available
   If not available, then which earliest date of visit is available in the file? ____________
8. Duration of the disease: _______________________
9. Method of Diagnosis or test done on the indicated earliest date of visit:
   HbA1c □ FBG □ OGTT □ RBS □ None □
10. Anti-diabetes drug therapy initiated on or put on at that earliest indicated date of visit:
    _______________________
    _______________________
11. Other parameters measured at initiation or at that earliest indicated date of visit:
    I. Blood pressure levels YES □ NO □
    II. Cholesterol levels YES □ NO □
    III. Weight YES □ NO □
    IV. Body Mass Index YES □ NO □
D. PATIENT MEASUREMENTS OF TREATMENT TARGETS MONITORED ON EVERY FOLLOW-UP VISIT AT THE FACILITY DURING THE 6 MONTHS OF THE STUDY PERIOD

12. Blood glucose levels:
   HbA1c □   FBG □   OGTT □   RBS □   None □  
   Measurement value: ______________ ______________ ______________
   Mean value:

13. Blood Pressure levels : YES □   NO □  
   Measurement value: ______________ ______________ ______________
   Mean value:

14. Cholesterol levels : YES □   NO □  
   Measurement value: ______________ ______________ ______________
   Mean value:

15. Weight (kgs) : YES □   NO □  
   Measurement value: ______________ ______________ ______________
   Mean value:

16. Body Mass Index : YES □   NO □  
   Measurement value: ______________ ______________ ______________
   Mean value:

E. Anti-diabetic Drug therapy as at the end study period (June 2015)
   ______________
   ______________
   ______________

F. Complications associated with Diabetes, identified since the time of diagnosis of the condition to the time of the study period.

17. Retinopathy/Eye problems YES □   NO □
18. Neuropathy/Nerve problems YES □   NO □
19. Nephropathy/Kidney problems YES □   NO □
20. Foot ulcers YES □   NO □
21. Amputation YES □   NO □
22. High Blood Pressure/Hypertension YES □   NO □
APPENDIX 2: INFORMED CONSENT PROCESS INFORMATION AND CONSENT FORM
Serial Number_______________ Version: 01 March 2015

STUDY TITLE: MANAGEMENT OF TYPE 2 DIABETIC PATIENTS AS PER PROTOCOLS AND ASSESSMENT OF PATIENTS’ OPINIONS ON PRACTICES WITH REGARD TO TAKING RESPONSIBILITY AT VIHIGA COUNTY REFERRAL HOSPITAL

A. CONSENT EXPLANATION INFORMATION
(for face to face Interview with adult type 2 diabetic patients)

Title of Study: Management of type 2 diabetic patients as per protocols and assessment of patients’ opinions, practices on responsibility at Vihiga County Referral Hospital

Institution: Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, P.O. BOX 30197-00400, Nairobi.

Investigator: Dr. Kaitany Benjamin, P.O. Box 5603-00506, Nairobi. Mobile +254 710339864

Supervisors: E.M. Guantai, Dr. M.N. Mulaku and Dr. B. Amugune. School of Pharmacy, University of Nairobi

Ethics Approval: Kenyatta National Hospital/ University of Nairobi Ethical Research Committee, P.O.BOX 20723-00100, Nairobi. Tel 2726300 / 2716450 Ext 44102.

Permission is requested from you to consider enrolling in this medical research as part of my degree; Master of Pharmacy in Pharmacoepidemiology and Pharmacovigilance work. You should understand the following general principles, which apply to all participants in a medical research:

i. Your agreement to participate in this study is voluntary.

ii. You may withdraw from the study at any time without necessarily giving a reason for your withdrawal.

iii. After you have read the explanation, please feel free to ask any questions that will enable you to understand clearly the nature of the study.

iv. The interview is anticipated to last 20-30 minutes.
**Introduction:** In this study, I am assessing the management of type 2 diabetic patients at Vihiga County Referral Hospital as per some official protocols and exploring patients’ opinions on practices regarding their responsibilities.

**Purpose of the study:** The purpose of this study is to determine the proportions of type 2 diabetic patients at Vihiga County Referral Hospital treated as per some official protocols and exploring patients’ opinions on practices regarding their responsibilities. You have been approached to participate because you have type 2 diabetes and have been managed at this hospital.

**Procedure:** With your permission I will engage you in a discussion about your opinions on practices regarding your responsibility to manage this condition through healthy eating, physical activity, self-monitoring of blood glucose and drug compliance. I will take notes of the discussion by pen and paper. All information will be handled with confidentiality.

**Risks:** This is a minimal risk study and there will be no physical or otherwise harm to you during the study. However, there may be some psychological and emotional risk associated with information disclosure by you during the interview. This will be minimized or completely eradicated by the investigator upholding effective confidentiality strategies. Only the principal investigator will handle the primary data that may have some elements of your direct identifiers. However no information collected will bear your name in it. Any other research assistants involved in data entry and analysis will handle the secondary data that will be delinked from the primary data.

**Benefits:** There will be no financial incentives or other direct benefits to you. However, the study findings may be useful later in improving the quality of care provided to type 2 diabetes patients, through clinician compliance to treatment guidelines in diagnosis, management and monitoring of such patients.

**Assurance of confidentiality:** All information obtained from you will be kept in confidence. At no point will your name be mentioned or used during data handling or in any resulting publications. Codes will be used instead. Your hospital number will be removed from the primary data we collect but codes used instead. The data will be stored under lock and key accessed only by the principal investigator. The electronic records will be password protected.

**Contacts:** In case you need to contact me or the Kenyatta National Hospital/University of Nairobi Ethics and Research Committee that has given ethical approval to this study
regarding your rights as a participant in this study please feel free to use the contacts provided on the consent form.

B. PARTICIPANT CONSENT FORM

I, the undersigned willingly agree to participate in the study. I have been explained and understood the nature of the study, my responsibilities as a study participant, the inconveniences associated with voluntary participation in the study and that all my questions and concerns relating to the study have been answered satisfactorily. I understand that I may choose to leave the study at any time and will not be penalized or prejudiced in any way. I understand that the information gathered will be used for the purpose of this study only and maximum confidentiality will be maintained.

I will receive a copy of this signed consent document to take away and keep.

Name and signature of study participant __________________ Date_____

INVESTIGATOR DECLARATION

I have explained the information in this document to this participant and encouraged them to ask questions which I took time to answer. I am satisfied that the participant adequately understands all aspects of the research as discussed in the consent process information document above.

Name and Signature of Person Obtaining Consent

_____________________________Date_____

Contacts:

INVESTIGATOR: DR. KAITANY BENJAMIN, P.O. BOX 5603-00506, NAIROBI. MOBILE +254 710339864
SECRETARY, KENYATTA NATIONAL HOSPITAL/ UNIVERSITY OF NAIROBI ETHICAL RESEARCH COMMITTEE, P.O. BOX 20723-00100, NAIROBI. TEL 2726300 / 2716450 EXT 44102
APPENDIX 3: DATA COLLECTION FORM (QUESTIONNAIRE) FOR PATIENTS’ DEMOGRAPHICS AND INFORMATION ON OPINIONS WITH REGARD TO PRACTICES ON SELF CARE BEHAVIOURS

Individual Diabetes Question Sheet

Patient initials _____________________________ Date __________________

To provide you with the best possible care, we need to know about your current eating patterns, medication, blood glucose testing, and your physical exercise. We need some basic information about you and your diabetes.

1. Are you (check one) _____ Male_____ Female
2. Are you employed :_____ Yes_____ No
3. Are you (check one) _____ Married_____ Single_____ Widowed_____ Divorced
4. How old are you? __________ years old
5. Any family history of diabetes : _____ Yes_____ No
6. How long have you had the disease :__________ years
7. Education level: _____ primary_____ Secondary_____ College
8. How much do you weigh? __________ kgs
9. What is your desired weight? What do you think would be a good, realistic weight for you? __________

A. Perceived Blood Glucose Control

1. How satisfied are you with your overall blood glucose control
   _____ I have excellent control  ____ I have a few problems
   _____ I have pretty good control  ____ I have poor control
   _____ I have good control  ____ I have very poor control

2. Do you have a target range for your blood glucose? That is, do you try to keep your blood sugar from getting lower or higher than certain values that you and your doctor or nurse have agreed on?
   _____ Yes  _____ No  _____ Not sure

3. Sometimes when you test your blood sugar, it can be too high. How often is this a problem for you?
4. Sometimes blood sugar can be too low causing hypoglycaemia (an insulin reaction). How often is this a problem for you?

<table>
<thead>
<tr>
<th>Option</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>My blood sugar is never too low</td>
<td></td>
</tr>
<tr>
<td>A couple times a month or less</td>
<td></td>
</tr>
<tr>
<td>Once or twice a week</td>
<td></td>
</tr>
<tr>
<td>Three to five times a week</td>
<td></td>
</tr>
<tr>
<td>Almost every day</td>
<td></td>
</tr>
</tbody>
</table>

Other comments:

**B. Knowledge and Skills on diet**

**During the past 3 months, how often did you:**

<table>
<thead>
<tr>
<th>Question</th>
<th>Never</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Use the information on the number of calories, carbohydrates or grams of fat in foods to decide what to eat?</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>2. Intentionally miss a meal or snack to cut calories or fat?</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>3. Intentionally take small amounts to cut calories, sugar or fat?</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>4. Use sugar free or reduced sugar products?</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times a day</td>
</tr>
<tr>
<td>5. Resist the desire to eat a food you want because it is too high in fat, sugar, or calories?</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times</td>
</tr>
</tbody>
</table>
### 6. Use a written meal procedure to decide what foods to eat?

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Never</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Times</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Other comments:**

### C. Diet Barriers

**During the past 3 months, how often have you had eating problems with each of the following?**

<table>
<thead>
<tr>
<th>Eating Problem</th>
<th>Frequency</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. When feeling stressed, anxious, depressed, angry, or bored.</td>
<td>Never</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>2 to 3 times/month</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>2. Because of having hunger or food cravings.</td>
<td>Never</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>2 to 3 times/month</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>3. Because family or friends tempt you or are not very supportive of your efforts to eat right.</td>
<td>Never</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>2 to 3 times/month</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>4. When eating away from home (restaurants)</td>
<td>Never</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>2 to 3 times/month</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>5. Because you feel deprived due to trying to follow a diet.</td>
<td>Never</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>2 to 3 times/month</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>6. Because you</td>
<td>Never</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>2 to 3 times/month</td>
<td>1 or more times daily</td>
</tr>
</tbody>
</table>
feel discouraged due to lack of results (e.g. no weight loss, high blood sugars).

7. Because you are busy with family, work, or other responsibilities.

<table>
<thead>
<tr>
<th>Never</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>2 to 3 times/month</th>
<th>1 or more times daily</th>
</tr>
</thead>
</table>

Other comments:

D. Use of Medicine

This section focuses on your use of medicines to treat diabetes.

1. Has your doctor prescribed tablets for your diabetes?
   - Yes  - No

2. How many times are you supposed to take these tablets?
   - I do not take tablets
   - Twice daily
   - Often as needed
   - Three or more times daily
   - Once daily

3. How many times do you end up taking these tablets?
   - I do not take the tablets
   - I miss a dose three to five times weekly
   - I never miss a dose
   - I miss a dose almost every day
   - I miss a dose a several times a month or less
   - I never take my prescribed pills
   - I miss a dose one or two times a week

4. Has the doctor prescribed insulin injection for your diabetes?
   - Yes  - No

5. How many times are you supposed to take insulin?
   - I do not take insulin
   - Twice a day
   - Often as needed
   - Three or more times a day
6. How many times do you end up taking your insulin?

_____ I haven’t been prescribed for insulin
_____ I never miss an injection
_____ I miss three to five times weekly
_____ I miss almost every day
_____ I miss several times a month
_____ I never take my prescribed insulin
_____ I miss once or twice a week

Other comments:

E. Medication Barriers

During the past 3 months, how often has each of the following caused a problem in taking your prescribed medicine?

<table>
<thead>
<tr>
<th>1. Feeling stressed, anxious, depressed, angry, or bored.</th>
<th>Never</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. The medication has unpleasant side effects.</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more a day</td>
</tr>
<tr>
<td>3. Family or friends are not very supportive.</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>4. When away from home (e.g., on vacation, business trips, at restaurants, parties).</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times daily</td>
</tr>
<tr>
<td>5. My daily program (waking, going to bed, eat, work, etc.) is different from one day to the other.</td>
<td>Never</td>
<td>1 time monthly or less</td>
<td>2 to 3 times/month</td>
<td>1 to 2 times/week</td>
<td>4 to 6 times/week</td>
<td>1 or more times daily</td>
</tr>
</tbody>
</table>
6. Feel discouraged due to lack of results (e.g., no weight loss, high blood sugars).

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Never</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
</table>

7. Too much occupied with family, work, or other responsibilities.

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Never</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
</table>

8. The medicines are too costly

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Never</th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>1 or more times daily</th>
</tr>
</thead>
</table>

Other comments:

F. Monitoring of blood glucose

The following questions have to do with testing your blood glucose

1. How many times have you been asked to test your blood glucose?

   _____ I have not been asked
   _____ Often as needed
   _____ Several times a month
   _____ 1 or 2 times a week
   _____ 3 to 6 times a week

   _____ Once a day
   _____ Twice a day
   _____ 3 or 4 times a day
   _____ 5 or more times a day

2. How many times do you actually test your blood glucose?

   _____ I have not been asked to test
   _____ Often as needed
   _____ Several times a month
   _____ 1 or 2 times a week
   _____ 3 to 6 times a week

   _____ Once a day
   _____ Twice a day
   _____ 3 or 4 times a day
   _____ 5 or more times a day

Other comments:
### G. Barriers to Blood Glucose Monitoring

In the past 3 months, how many times has each of the following caused a problem in testing blood glucose?

| 1. Feeling stressed, anxious, depressed, angry, or bored. | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
| 2. I hate to prick myself. | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
| 3. Family or friends are not very supportive. | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
| 4. When away from home (e.g., on vacation, business trips, at restaurants, relatives). | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
| 5. My daily program (waking, going to bed, eat, work, etc.) is different from one day to the other. | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
| 6. Feel discouraged due to lack of results (e.g., no weight loss, high blood sugars). | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
| 7. Too much occupied with family, work, or other responsibilities. | Never | 1 time monthly or less | 2 to 3 times/month | 1 to 2 times/week | 4 to 6 times/week | 1 or more times daily |
H. Physical Exercise

The following questions are about your level of physical activity.

1. Has the doctor told you to get more exercise?
   _____ Yes  _____ No  _____ Don’t know

2. How active is your daily routine? How much physical activity do you get as a result of going to work, yard work, shopping, housework, and other daily activities?
   _____ Very inactive  _____ A moderate amount of activity
   _____ Inactive  _____ Active
   _____ A little activity  _____ Very active

3. How many times do you set aside time to exercise. How many times do you do something physically active like cycling, going to the gym, walking, running or participating in sports?
   _____ I never exercise  _____ 5 to 6 times a week
   _____ A couple times a month  _____ Once a day
   _____ 1 or 2 times a week  _____ More than once a day
   _____ 3 to 4 times a week

Other comments:

I. Barriers to Exercising

In the past 3 months, how many times have you had trouble exercising because of each of the following?

1. Feeling stressed, anxious depressed, angry, or bored.
   _____ I never exercise  _____ 1 time
   Never 1 time monthly or less 2 to 3 times/month 1 to 2 times/week 4 to 6 times/week 1 or more times daily
<table>
<thead>
<tr>
<th></th>
<th></th>
<th>1 time monthly or less</th>
<th>2 to 3 times/month</th>
<th>1 to 2 times/week</th>
<th>4 to 6 times/week</th>
<th>daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Exercise and physical activity cause pain and discomfort for me.</td>
<td>Never</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Feeling that Family and friends are not very supportive.</td>
<td>Never</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. When away from home (e.g., on Vacation, business trips, at relatives).</td>
<td>Never</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Felt discouraged because of lack of results (e.g., no weight loss, high blood sugars).</td>
<td>Never</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Too much occupied with family, work, or other responsibilities.</td>
<td>Never</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX 4: FOMU YAKUIDHINISHA U TARATIBU WA KUKUSANYA U JUMBE NA MAAFIKIANO

Nambari ya usajili___________mtindo:01                  Tarehe: Machi, 2015

MADA YA UTAFITI: UTHIBITISHAJI WA UGONJWA WA KISUKARI AINA YA PILI KULINGANA NA UTARATIBU NA TATHMINI, MAONI NA MASUALA YA RUFAA YA KAUNTI YA VIHIGA.

A. Ujumbe wa kuidhinisha maelezo
(Kwa usaili wa ana kwa ana na mgonjwa wa ugonjwa wa kisukari aina ya pili)

Mada ya utafiti: kudhibiti wagonjwa wa kisukari aina ya pili kulingana na itafiki na tathmini ya wagonjwa, maoni na mazoezi kulingana na majukumu ya hospitali ya rufaa ya kaunti ya Vihiga.

Chuo: Idara ya famakologija na famakognsia, chuo cha famasia behewa la Nairobi, SLP 30197-00400, Nairobi.


Idhinisho la kimaadili


i. Mwitikio wako wa kushiriki katika utafiti huu ni wa hiari.
ii. Unaweza kujitaka kutoka kwa utafiti huu wakati wowote pasipo kuhitajika kutoka sababu za kujitaka.
iii. Baada ya kufanya maelezo tafadhali, una uhuru wa kuuliza maswali yoyote yatakatayokuwesha kuelewa vizuri aina tofauti.
iv. Usahili huu unakadiriwa kuchukua muda wa dakika 20-30.

Utangulizi: Katika utafiti huu, natathmini njia za kudhibiti wagonjwa wa kisukari aina ya pili kulingana na utaratibu na kukaguzi wa maoni ya wagonjwa na majukumu katika hospitali ya rufaa ya kaunti ya Vihiga.

Lengo la utafiti: Lengo la utafiti huu ni kujua kiwango cha kudhibiti wagonjwa wa kisukari aina ya pili kwa muhibi wa utaratibu na ukaguzi wa maoni ya wagonjwa kulingana na majukumu katika hospitali ya rufaa ya kaunti ya vihiga.

Hatari: Hakuna hatari yoyote kwa kuwa atakayeshirikiwana hataumizwa lakini kunaweza kuwa na adhari za kusaikolobia au adhari za kihiisia zinazohusiana na ujumbe ambaye anayesaidiwa atatoa wakati wa usajili. Tutapunguza au kumaliza hisia hizi kabisa kwa kuuweka ujumbe gushi na anaweza kuowenteza baadhi ya vipengee kumwezeshwa kubaini aliyetoa. Wazaidizi wake wowote watapata ujumbe na maelezo kutoka kwa msajili na ujumbe wenyeve hakuwa na ushusiano wa moja na ule uliotolewa na aliyesajiliwa.


Mawasiliano: Iwapo ungetaka kuwasiliana nami, ama hospitali kuu ya Kenyatta choo kikuu cha Nairobi maadili na kamati ambayo imeniruhusu kufanya utafiti huu, kuwa huru na utumie nambari za mawasiliano zilizoorodheshwa kwenye fomu hii.

FOMU YA IDHINI YA MSHIRIKI
Mimi niliyeleza sahihi kwa hiari nakubali kushiriki utafiti huu. Nimeelezwa na kuelewa kinachohusiana na utafiti huu, majukumu yangu katika utafiti huu, athari zinazoweza kutokana na kujitolea kwangu na kuwa maswali yote yanayohusiana na utafiti huu nimeyajibuzwa kama inavyotakikana. Naelewa kuwa ujumbe uliokusanyuka utatangazeka kwa lengo la utafiti, utafiti huu utakaochukuliwa kwa ajili ya utafiti wa hospitali choo ya Kenyatta cha Nairobi maadili na kamati ambayo imeniruhusu kufanya utafiti huu kwa ajili ya utafiti wa hospitali choo ya Kenyatta cha Nairobi maadili na kamati ambayo imeniruhusu kufanya utafiti huu. Nitapokea nakala ya fomu hii iliyojipika sahihi.

Jina na sahihi ya mshiriki wa utafiti ______________________ tarehe_______________

MIADI YA MTAFITI
Nimeelewa kuwa ujumbe katika fomu hii kwa mshiriki huyu kwa nimewatia wote moyo ili kuuliza maswali ambayo nilichukua kwa hospitali kuu ya Kenyatta choo kikuu cha Nairobi maadili na kamati ambayo imeniruhusu kufanya utafiti huu kwa ajili ya utafiti wa hospitali choo ya Kenyatta choo kikuu cha Nairobi maadili na kamati ambayo imeniruhusu kufanya utafiti huu. Nitapokea nakala ya fomu hii iliyojipika sahihi.

Jina na sahihi ya mshiriki wa utafiti ______________________ tarehe_______________

MAWASILIANO
Mtaitfii: Dkt. Kaitany Benjamin SLP 5603-00506,Nairobi. Simu +254 710 339 864 .Sekritari,
, Hospitali kuu ya Kenyatta choo kikuu ya Nairobi maadili na mshiriki wa utafiti, SLP 20723-00100
Nairobi simu 2726300-2716450 ext 44102.
APPENDIX 2: FOMU YA KUKUSANYA WUMBE(MASWALI) KUHUSU WAGONJWA WA KISUKARI MAONI NA MAZOEZO NA NJIA ZA KUJITUNZA

MASWALI YA KIBINAFSI KUHUSU UGONJWA WA KISUKARI

Jina la magonjwa kimkato_____________________tarehe____________________

Ili kukupa utunzaji bora, tunahitaji kujua hivi punde za kula, dawa kujipima kiwango cha glukosi katika damu na mazoezi ya misul.jibu kila swali kwa ukweli ufaao kabisa.tutatumia majibu yako kutatua shida unazozipata unapodhibiti ugonjwa wa kisukari .

Tunahitaji ujumbe wa kukuhusu wewe na ugonjwa wa kisukari

1. (Chagua moja) Jinsia yako_____________________kiume ________ Kike
2. Umeajiriwa___________________________ndio ___________________________la
3. (chagua moja)______umeolewa/umeoa______hujaoa/hujadewa_______umetalikiana
4. Una umri gani?_________________________miaka
5. Kuna historia ya ugonjwa wa kisukari katika familia yenu?_______ndio_____la
6. Umekuwa na ugonjwa huu kwa muda gani? miaka __________________________
7. Kiwango cha elimu:_______shule ya msingi_______chuo cha upili_________chuo
8. Una uzito gani? kilo________________________
9. Ungependelea kuwa na uzito gani? Ni uzito gani unadhani ni mzuri kwako na unakufaa?kilo________________________

Njia za kuaminika za kudhibiti za kudhibiti glukosi

1. Umeridhikaje na kiwango cha glukosi katika damu?
   __________nimeshibiti kabisa__________________________nina sjida chache
   __________nimejabibu sana__________________________nimechabiti vobaya
   __________nimechabiti kabisa ____________________________sijadhibiti kabisa

2. Una lengo la kiwango cha glucose katika damu? Yaani, unajaribu kudhibiti kiwango cha sukari kisipande au kutemka kuliko kinavyostahili kulingana na ushauri wa daktari?
   __________ndio __________la__________sina uhakika

3. Wakati mwingine unapopima kiwango cha sukari kwenye damu, kinaweza kuwa cha juu sana. Hufanyika mara ngapi kwako?
   ________________kiwango cha sukari katika damu huwa hakipandi sana
   ____________________mara kadhaa kwa mwezi au chini yake
   ______________________mara moja au mbili kwa wiki
   ______________________mara tatu hadi tano kwa wiki
   ______________________takribani kila siku

4. Wakati mwingine kwango cha sukari kwenye damu huwa kiko chini sana, hii hutokea mara ngapi kwako?
Kiwango changu cha sukari kwenyenye damu huwa hakiteremki sana
Mara kadhaa kwa mwezi au mara chache kwa mwezi
Mara moja au mbili
Mara tatu hadi tano kwa wiki
Takribani Kila siku

**Maoni Mengi:**

### B. Maarifa na Ujunzi Kuhusu Chakula

**Kwa muda wa miezi mitatu iliopita, ni mara ngapi ulifanya yafuatayo?**

| --- | --- | --- | --- | --- | --- |
Maoni Mengine:

**C. Vizuizi Vya Chakula Kifaacho**

*Katika kipindi cha miezi mitatu iliyopita, ni mara ngapi ulikuwa na shida hizi?*

|----------------|----------------------------------------------------|-----------------------------|----------------------------------|-------------------------------|----------------------------------|

*Vingi?*

6. Unatumia menu au mpangilio wa chakula kabla ya kuama chakula utakachokula? Hakuna

*Mara moja au mbili kwa siku.*
6. **Shida za kula kwa sababu unahisi kuvunjwa moyo kwa kukosa matokeo bora (Kukosa kupunguza uzito, kwango cha juu cha sukari).**

<table>
<thead>
<tr>
<th>Mara moja kwa mwezi au chini ya mara moja kwa wiki</th>
<th>Mara moja kwa wiki</th>
<th>Mara moja kwa siku</th>
<th>Mara moja nne au siti</th>
<th>Mara moja nne au siti zaidi</th>
<th>Mara moja nne au siku</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mara mbili au chini ya mara moja kwa mwezi</td>
<td>Mara mbili hadi tatu kwa mwezi</td>
<td>Mara mbili kwa mwezi</td>
<td>Mara mbili kwa wiki</td>
<td>Mara mbili kwa wiki</td>
<td>Mara mbili kwa siku</td>
</tr>
</tbody>
</table>

Hakuna

7. **Shida za kula kwa kuwa na shughuli nyingi za familia, kikazi au majukumu.**

<table>
<thead>
<tr>
<th>Mara moja kwa mwezi au chini ya mara moja kwa wiki</th>
<th>Mara moja kwa mwezi au chini ya mara moja kwa wiki</th>
<th>Mara moja nne au siti</th>
<th>Mara moja nne au siti zaidi</th>
<th>Mara moja nne au siku</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mara mbili au chini ya mara moja kwa mwezi</td>
<td>Mara mbili hadi tatu kwa mwezi</td>
<td>Mara mbili kwa mwezi</td>
<td>Mara mbili kwa wiki</td>
<td>Mara mbili kwa siku</td>
</tr>
</tbody>
</table>

Maoni Mengine:

<table>
<thead>
<tr>
<th>D. <strong>Matumizi ya Dawa:</strong></th>
</tr>
</thead>
</table>

**Sehemu hii inahusiana na matumizi ya matibabu ya ugonjwa wa kisukari.**

7. Daktari wako amekushauri utumie tembe za ugonjwa wa kisukari?
   
   _____ Ndio                     _____ La

8. Unafaa kumeza tembe hizi mara ngapi?

   _____ Huwa simezi tembe hizi            _____ Mara Mbili kwa siku

   _____ Mara tu ninapohitajika kumeza_____ Mara tatu au zaidi kwa siku

   _____ Mara Moja kwa siku

9. Ni mara ngapi unajipata ukitumia tembe hizi?

   _____ Huwa simezi tembe hizi kabisa

   _____ Huwa sikosi dozi

   _____ Nakosa dozi mara kadhaa kwa mwezi au chini ya mwezi

   _____ Huwa nakosa dozi mara moja au mbili kwa siku

   _____ Nakosa dozi mara tatu hadi tano kwa wiki

   _____ Nakosa dozi takribani kila siku.
10. Je, daktari amekushauri kutumia insulin kudhibiti sukari ya damu?
   _____ Ndio   _____ La

11. Unafaa kutumia insulin mara ngapi?
   _____ Huwa situmii insulinini   _____ Mara mbili kwa siku
   _____ Mara kadhaa inavyohitajika   _____ Mara tatu au zaidi kwa siku
   _____ Mara moja kwa siku

12. Ni mara ngapi unajipata ukitumia insulin?
   _____ Sijashauriwa kutumia insulin kudhibiti kiwango cha sukari kwenye damu
   _____ Nakosa mara tatu hadi tano kwa wiki
   _____ Nakosa mara kadhaa kwa mwezi
   _____ Nakosa mara moja au mbili kwa wiki
   _____ Nakosa takribani kiliciku
   _____ Huwa sikosi kama nilivyolekezwa kutumia

Maoni Mengine:

E. Vizuizi Vya Matibabu

Muda wa miezi mitatu iliyopita, ni mara ngai umekuwa na shida zifuatazo na kuadhiri matumizi ya dawa ulizolezewa?

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Mawazo mengi au hasira</td>
<td>Hakuna</td>
<td>Mara moja au chini ya mara moja kwa mwezi</td>
<td>Mara moja au mbili kwa mwezi</td>
<td>Mara moja au mbili kwa wiki</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. Mpangilio wa kazi yangu za kila siku. (Kutembea, kwenda kulala, kula ni tofauti kila siku).


8. Dawa zingine ni ghali/bei yake iko juu

Maoni Mengine:

F. Kudhibiti Kiwango cha Glukosi Kwenye Damu

Maswali machache yafuatayo yanahusu kupima kiwango cha glukosi katika damu.

3. Umeshauriwa upime kiwango cha glukosi kwenye damu mara ngapi?
   _____ Sijaambiwa nipime kwango cha glukosi kwenye damu
   _____ Mara kwa mara inavyohitajika
   _____ Mara kadhaa kwa mwezi kwa siku

Maoni:
_____ Mara moja au mbili kwa wiki
_____ Mara tatu hadi sita kwa wiki
_____ Mara moja kwa siku
_____ Mara mbili kwa siku
_____ Mara tatu hadi nne kwa siku
_____ Mara tano au zaidi kwa siku

4. Kwa hakika, unapima kiwango chako cha glukosi katiaka damu mara ngapi?

_____ Sijaambiwa nipime kiwango cha glukosi _____ Mara kadha wa kadha
inavyohitajika
_____ Mara moja au mbili kwa wiki
_____ Mara tatu hadi sita kwa wiki
_____ Mara mbili kwa siku
_____ Mara tano au zaidi kwa siku

Maoni Mengine:

G. Vizuizi unapodhibiti kwango cha Glukosi Katika Damu

Kwa miezi mitatu iliyoita, in mara ngapi shida zifuatazo zimeadhiri upimaji wa kusango cha glukosi kwene mwili?

<table>
<thead>
<tr>
<th>No</th>
<th>Wazo mengi, wasiwasi, hasira, kukinai.</th>
<th>Hakuna</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mara moja au chini ya mara moja kwa mwezi</td>
<td>Mara moja kwa mwezi</td>
</tr>
<tr>
<td>1</td>
<td>Mara mbili hadi tatu kwa mwezi</td>
<td>Mara moja hadi mbili kwa wiki</td>
</tr>
<tr>
<td></td>
<td>Mara nne hadi kwa wiki</td>
<td>Mara moja au zaidi kwa siku</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No</th>
<th>Naogopa kujumiza kwa kujidunga sindano.</th>
<th>Hakuna</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mara moja kwa mwezi au chini ya mara moja kwa wiki.</td>
<td>Mara moja kwa mwezi</td>
</tr>
<tr>
<td>2</td>
<td>Mara mbili hadi tatu kwa mwezi.</td>
<td>Mara moja au mbili kwa wiki.</td>
</tr>
<tr>
<td></td>
<td>Mara nne hadi kwa wiki.</td>
<td>Mara moja au zaidi kwa siku.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No</th>
<th>Familia na marafiki hawaniungi mkono.</th>
<th>Hakuna</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mara moja kwa mwezi au chini ya mara moja kwa wiki.</td>
<td>Mara moja kwa mwezi</td>
</tr>
<tr>
<td>3</td>
<td>Mara mbili hadi tatu kwa mwezi.</td>
<td>Mara moja au mbili kwa wiki.</td>
</tr>
<tr>
<td></td>
<td>Mara nne hadi kwa wiki.</td>
<td>Mara moja au zaidi kwa siku.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No</th>
<th>Nikiwa siko nyumbani (likizo, ziara</th>
<th>Hakuna</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mara moja kwa mwezi</td>
<td>Mara moja kwa mwezi</td>
</tr>
<tr>
<td>4</td>
<td>Mara mbili</td>
<td>Mara moja au</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mara nne</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mara moja</td>
</tr>
</tbody>
</table>
za kikazi, hotelini au na jamaa). au chini ya mara moja kwa wiki. hadi tatu kwa mwezi. mbili kwa wiki. hadi sita kwa wiki au zaidi kwa siku.

5. Ratiba ya shughuli za kila siku (kutembea, kwenda kulala, kula, kazi na kadhalika).

Hakuna Mara moja kwa mwezi au chini ya mara moja kwa wiki. Mara mbili hadi tatu kwa mwezi. Mara moja au mbili kwa wiki. Mara nne hadi sita kwa wiki Mara moja au zaidi kwa siku

6. Huwa navunjwa moyo na kukosa matokeo bora (sipunguzi uzani, kwango cha juu cha sukari kwenye damu).

Hakuna Mara moja kwa mwezi au chini ya mara moja kwa wiki. Mara mbili hadi tatu kwa mwezi. Mara moja au mbili kwa wiki. Mara nne hadi sita kwa wiki Mara moja au zaidi kwa siku


Hakuna Mara moja kwa mwezi au chini ya mara moja kwa wiki. Mara mbili hadi tatu kwa mwezi. Mara moja au mbili kwa wiki. Mara nne hadi sita kwa wiki Mara moja au zaidi kwa siku

8. Vifaa vya kujipima ni ghali (kama glukomita)

Hakuna Mara moja kwa mwezi au chini ya mara moja kwa wiki. Mara mbili hadi tatu kwa mwezi. Mara moja au mbili kwa wiki. Mara nne hadi sita kwa wiki Mara moja au zaidi kwa siku

Maoni Mengine:

H. Mazoezi Ya Mwili

Maswali matano yafuatayo yanahusu kiasi cha mazoezi ya viungo.

1. Daktari wako amekushauri kufanya mazoezi zaidi?

_____ Ndio  _____ La  _____ Sijui

2. Shughuli zako za kila siku zinahusisha mazoezi? Ni kiasi gani cha mazoezi unapata katika kwenda kazini, kwenda shambani na kazi nyingine za kila siku?

_____ Hakuna mazoezi kabisa  _____ Hakuna mazoezi
3. Umetenga kiasi gani cha wakati cha kufanya mazoezi? Unafanya mazoezi ya viungo mara ngapi kama kutembea, kukimbia, kuendesha baiskeli, kwenda katika vyumba vya mazoezi ama kushiriki michezo?

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Maoni Mengine:

I. Exercise Barriers

Kwa kipindi cha miezi mitatu iliypita, ni mara ngapi umpata shida ya kufanya mazoezi kwa sababu ya mambo haya?

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Iwapo hauko nyumbani (mfano likizo, ziara ya kibiashara, kwa

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5. Unavunjwa moyo na kukosa matokeo bora (mfano kukosa kupoteza uzito kiwango cha juu cha sukari kwenye damu).

6. Umeshikika sana na familia kazi au majukumu mengine.
APPENDIX 4: KNH-UON ERC APPROVAL LETTER

UNIVERSITY OF NAIROBI
COLLEGE OF HEALTH SCIENCES
P O BOX 19766 Code 0202
Telegram: varity
(254-029) 2726300 Ext 44355

KNH-UON ERC
Email: uonkhn_erc@uonbi.ac.ke
Website: http://www.erc.uonbi.ac.ke
Facebook: https://www.facebook.com/uonkhn
twitter: @UONKHN_ERC https://twitter.com/BDORKH_ERC

Ref: KNH-ERC/A/1

Kaitany Benjamin Kiplagat
Reg. U5177533/2014
Dept.of Pharmacology and Pharmacognosy
School of Pharmacy
College of Health Sciences
University of Nairobi

Dear Benjamin

Revised research proposal: Management of Type 2 Diabetic patients at Vihiga County Referral Hospital:
Compliance with Guidelines and the role of patients (P841/10/2015)

This is to inform you that the KNH-UoN Ethics & Research Committee (KNH-UoN ERC) has reviewed and approved your
above proposal. The approval periods are 6th January 2016 -5th January 2017.

This approval is subject to compliance with the following requirements:

a) Only approved documents (informed consents, study instruments, advertising materials etc) will be used.
b) All changes (amendments, deviations, violations etc) are submitted for review and approval by KNH-UoN ERC before
implementation.
c) Death and life threatening problems and serious adverse events (SAEs) or unexpected adverse events whether
related or unrelated to the study must be reported to the KNH-UoN ERC within 72 hours of notification.
d) Any changes, anticipated or otherwise that may increase the risks or affect safety or welfare of study participants and
others or affect the integrity of the research must be reported to KNH-UoN ERC within 72 hours.
e) Submission of a request for renewal of approval at least 60 days prior to expiry of the approval period. (Attach a
comprehensive progress report to support the renewal)
f) Submission of an executive summary report within 90 days upon completion of the study.
   This information will form part of the data base that will be consulted in future when processing related research
   studies so as to minimize chances of study duplication and/or plagiarism.

For more details consult the KNH-UoN ERC website http://www.erc.uonbi.ac.ke

6th January 2016